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The risk of tuberculosis infection in a healthy immuno-competent person is 10% per 
lifetime.  This risk increases to 10% per annum in HIV infected persons due to a 
progressive decline in CD4 T cell numbers.  In South Africa the estimated annual 
incidence of tuberculosis is 940 cases per 100,000 people.  HIV infection is currently the 
greatest risk factor for developing tuberculosis in South Africa.  The rate of HIV and 
tuberculosis co-infection in South Africa is estimated to be 53%.    
 
Combination anti-retroviral treatment (cART), suppresses viral replication, resulting in 
an increase in the number of CD4 T cells as well as the restoration of antigen specific 
immune responses.  In Cape Town, and elsewhere, the use of cART has been shown to 
reduce the incidence of tuberculosis in HIV infected people, by up to 80%.  Since cART 
has no known anti-mycobacterial action, this reduction in incidence may be due to the 
restoration of MTB specific immune responses.  cART  reduces the risk of tuberculosis in 
HIV infected people. Therefore a novel approach to gain insight into protection against 
tuberculosis is to analyse the T cells that expand in people sensitised by MTB during 
cART.   
 
The objectives of this dissertation was to longitudinally analyse CD4 T cell subsets 
during the first year of cART, from the time of starting cART (day 0), in HIV infected, 
MTB sensitised adults.  Peripheral blood mononuclear cells were obtained on day 0, 
weeks 2, 4, 12, 24, 36 and 48 of cART and were stimulated with Purified Protein 
Derivative (PPD), followed by flow cytometry to analyse surface markers and 
intracellular cytokines. 
 
CD4+ T cell numbers and proportions significantly increased during follow up and the 
viral load fell to undetectable levels in each patient, indicating successful immune 
restoration.  Central memory CD27+CD45RA- and CD27+CCR5- CD4+ cells expanded by 












Terminally differentiated effector CD4+CD27-CCR7- cells decreased by 12 weeks 
(p=0.02), paralleled by a proportional decline of PPD specific CD4+IFN-γ+ cells 
(p=0.02).  However the absolute numbers of PPD specific IFN-γ producing cells, 
determined by ELISpot, increased (p=0.02).  
 
Rapid effector responses are often measured when evaluating immunity.  This study 
shows that while cART is associated with an absolute increase in effector function, the 
proportional response decreased and the strongest correlate of increased cART mediated 
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Chapter 1.  Introduction 
 
1.1.  Tuberculosis 
 
1.1.1. Epidemiology 
Mycobacterium tuberculosis (MTB) DNA has been amplified from the tissues of 
Egyptian mummies more than 5000 years old (1).  Despite being an old, treatable and 
curable disease, the 2008 WHO-Stop TB partnership fact sheet reports 1.7 million deaths 
due to Tuberculosis (TB) and 9.2 million new cases of TB in 2006 (2).  It is estimated 
that more than 2 billion people, about one-third of the worlds population, have been 
exposed to MTB (3). 
 
 
Figure 1.  Global Tuberculosis Incidence (5).   
 
A 2006 report by the Health Systems Trust indicated the national prevalence in South 
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Of the 22 countries defined as being high burden, and responsible for 80% of global TB, 
South Africa is ranked as number 7 globally and number 4 in Africa.  Of the global cases 
of human immunodeficiency virus (HIV)-TB co-infection, 85% occurred in Africa in 
2006.  Of those, 28% occurred in South Africa (5).  In South Africa the risk of 
developing active TB in HIV-TB co-infected people was shown to be 10.4% per annum 
and exceeding 30% per annum in people with WHO stage 3 and 4 disease (6).  A study in 
a cohort of mine workers found that the risk of TB infection doubled within a year of 
acquiring HIV infection (7).  A recent report on cause of death in South African miners 
showed TB to be the leading cause of death in HIV infected persons who had died of 
natural causes (8).     
1.1.2. The organism  
The bacterium, MTB, was first isolated by Robert Koch and established as the causative 
organism of TB humans in 1882.  MTB is a rod shaped, aerobic, obligatory intracellular 
organism with an acid-fast cell wall.  It is a slow growing organism with a doubling time 
of about 20 hours (1).   
 
The composition of the MTB wax-rich cell wall includes highly cross-linked 
peptidoglycan and glycolipids, especially mycolic acids, the latter accounting for more 
than 60% of the cell wall.  Polysaccharides such as glucan, mannan, arabinomannan, and 
arabinogalactan are attached to the lipids.  The lipid content of the cell wall results in the 
hydrophobic nature of the bacillus which is associated with resistance to acidic and 
alkaline compounds, resistance to antibiotics, long term drug treatment, resistance to 
injury by human immune mechanisms, chronic infection and disease, impermeability to 
stains, acid fastness and difficulty in laboratory identification (9). 
 
1.1.3. Pathogenesis 
TB is an infectious disease acquired via the inhalation of MTB in airborne droplet nuclei.  
People with active pulmonary tuberculosis disease produce the airborne droplet nuclei 
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The droplet nuclei, 1-5um in diameter, remain airborne for minutes to hours and 
facilitates transmission of the organism via the airborne route (10).  
 
 After inhalation into the lung, resident phagocytic cells engulf MTB, which includes 
alveolar macrophages, dendritic cells (DC), and neutrophils.  Thus a local infection is 
established (11).  The events that follow allows for the description of various stages of 
TB infection. 
 
In the first stage, MTB avoids intracellular destruction and multiplies within the infected 
cells.  Growth and multiplication of the bacilli causes death and disruption of the infected 
cells and subsequently the bacilli are spilled into the immediate vicinity.  The bacilli and 
necrotic cellular debris initiate an inflammatory response, attracting phagocytic immune 
cells to the site of infection (12).   
 
These infiltrating cells engulf the bacilli, leading to further multiplication and increase in 
the bacillary load.  Macrophages and DC bearing MTB antigens migrate to regional 
lymph nodes and stimulate the generation of MTB recognising lymphocytes.  Migration 
of these lymphocytes to the site of infection results in activation of infected, as well as, 
infiltrating macrophages to kill the bacilli or inhibit its intracellular growth (13).  
 
This marks the start of the second stage, which results in the formation of a granuloma at 
the site of infection and the reduction of the bacillary load.  A granuloma is a well-
organized structure of cells characterized by a solid causeous center consisting of necrotic 
debris and infected cells (14).   
 
Giant multinucleated cells typically surround this center as well as a layer consisting of 
lymphocytes, fibroblasts, and blood-monocyte derived macrophages.  Live bacilli in the 
centre are deprived of oxygen and nutrients and enter into an altered state of metabolism 
in which they remain viable but may not be replicating.  The granuloma thus restricts the 
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Within the first one to three years of infection, about 5% of infected people experience 
impaired granuloma formation and the solid caseous centre begin to soften and liquefy 
resulting in a rich environment suitable for the extracellular growth and replication of 
MTB.  The infection spreads via the intrapulmonary lymphatic channels and enlarged 
lymph nodes can rupture into the adjacent airways causing tuberculous 
bronchopneumonia (16).   
 
This is referred to as an Acute Primary infection and symptoms include chronic fatigue, 
progressive weight loss, and the production of a chronic and contagious cough.  In the 
lung, extensive tissue damage occurs as a result of the host’s inflammatory response.  The 
infection can range from self-limiting tuberculosis pleuritis to more severe hematogenous 
dissemination of the infection throughout the body known as miliary TB (17).   
 
               Acute Primary infection                             Latent Tuberculosis infection                                            
 
 
                               1-3                  4-50    
       Years after infection 
Figure 2.  Stages of tuberculosis infection, adapted from PeterAnderson (18).   
 
Active disease develops in about 10% of infected people (19).  The rest will contain the 
infection, developing a latent form of the disease, Latent Tuberculosis Infection (LTBI).  
LTBI is defined as the existence of an immune response to the bacilli without the signs 
and symptoms of active tuberculosis disease.  This state of infection can be maintained 
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In about 5-10% of latently infected people, a third stage of TB infection occurs when the 
host’s immune status changes, leading to the loss of granuloma maintenance, 
reactivation, growth and dissemination of the bacilli and the development of active 
disease.  This is referred to as secondary acute infection and can occur due to 
immunosuppressive therapy, old age, malnutrition, and HIV infection (21).   
 
The risk of developing reactivation tuberculosis in the immunocompetent host is about 
10% per lifetime as compared to an approximate 10% per annum risk in HIV co-infected 
people (22)(23). 
1.1.4. Treatment 
Treatment of active TB by the administration of anti-tuberculous drugs is associated with 
cure rates of up to 82% (24).  However, antibiotic regimes used for treatment of active 
TB, requires a treatment length of at least six months.  The necessity for long-term 
treatment has contributed to poor treatment adherence, which may be compounded by 
other factors such as re-treatment, poor medical supervision, irregular supply of drugs 
and inappropriate drug dosage.  All together these factors have contributed to the 
emergence of TB drug resistance and thereby, as a countermeasure, to the 
implementation of directly observed therapy (DOT), which ensures that the patient is 
seen to be swallowing the medication in the presence of a trained supervisor (25). 
 
Multi-drug resistant TB (MDR-TB) is described as resistance to at least isoniazid and 
rifampicin, considered as two of the most powerful anti-tuberculous drugs available (26).  
 
 In 2003 the WHO estimated that globally, 50 million people may be infected with drug 
resistant strains of MTB.  It also reported that 79% of MDR-TB was resistant to three or 
more drugs (27).  The authors of a survey, based on 9 880 383 new and previously treated 
cases notified in 184 countries in 2004, showed that 4.3% (424 203) of these cases were 
MDR-TB.  They found a positive correlation between the proportion of patients who had 
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Extensively drug resistant TB (XDR-TB) is described as MDR-TB plus resistance to   
one of the injectable drugs used in TB treatment regimes (Kanamycin, Amikacin, and 
Capreomycin), as well as resistance to one of the quinolones (Ofloxacin, Ciprofloxacin), 
used in TB treatment regimes (26).  Based on this definition of XDR-TB, South Africa 
had reported more than 300 cases of XDR-TB by December 2006.  In September 2006, a 
new strain of XDR-TB in Tugela Ferry, in the province of Kwazulu-Natal, South Africa 
was reported.  In 2005, 221 of 544 people in the area had MDR-TB.  Of the 221 MDR-
TB cases, 53 were identified as MDR-TB plus resistance to at least three of six classes of 
second-line anti-tuberculous agents.  All 53 cases were HIV infected.  Of the 53 cases, 52 
died with a median survival time of 16 days from the time of sputum collection (29). 
 
The current statistics on TB drug resistance emphasises the need for the development of 
new and effective anti-tuberculous drugs that will shorten the length of treatment (30). 
 
1.1.5.  Vaccination 
In 1921, Albert Calmette and Camille Guerin developed a vaccine against TB using a live 
attenuated strain of Mycobacterium bovis (M.bovis) the cause of bovine TB.  The 
vaccine, Bacillus Calmette- Guerin (BCG) was first tested in infants in 1921 and has 
since been administered to about 3 billion people to date.  However, the analysis of 
numerous clinical trials showed that the protection afforded by BCG vaccination has 
ranged from as much as 82% to as little as 7%.  In 46-100% of cases, BCG vaccination 
has protected against severe forms of TB in childhood, such as TB meningitis and 
disseminated TB (31).   
 
However this protective efficacy varies dramatically during adolescence and adulthood in 
which pulmonary TB is the more prevalent form of TB and ranges from as much as 80% 
protection in the United Kingdom to as little as 5% in India.  Factors thought to 
contribute to these discordant results include route of administration, vaccine dose, 
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It is estimated that BCG vaccination has prevented only 5% of deaths due to TB.  The 
availability of the genome sequence of MTB as well as M.bovis, has increased the 
identification of new genes and antigens which has facilitated the development of various 
new vaccine candidates, some of which have already entered Phase I and II clinical trials 
(33).   
 
The successful development of a vaccine requires understanding of the protective 
immune response as well as correlates of protection.  Neither the immune response to 
MTB nor reliable correlates of protection thereof, have been completely defined.  In 
addition, it is not clearly understood why BCG vaccination has failed in some 
populations.  As a result, current estimates of the time required to develop a new vaccine 
against TB is about 20 years.  The development of vaccines effective in all populations, 
especially the immunocompromised, will be facilitated by further studies aimed at 
unraveling the complexity of the interactions that take place in the host-pathogen 
relationship (34). 
 
1.2.   The immune response to MTB infection 
The human immune response is composed of the innate and acquired elements.  The two 
elements are distinct but function in a synergistic manner (35). 
 
The cells of both the compartments originate from pluripotent hematopoietic stem cells in 
the bone marrow from which lymphoid and myeloid progenitors arise.  Lymphoid 
progenitors differentiate into lymphocytes of the acquired response as well as the natural 
killer (NK) cells of the innate response.  Myeloid progenitors differentiate into the 
granulocytes of the innate response, i.e. neutrophils, monocytes, macrophages, DC, and 
mast cells (36).   
 
The specificity of the innate cell receptors are genetically predetermined, as they are 
germ-line encoded, and recognise highly conserved, invariant structures that are shared 
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These microbial structures are referred to as pathogen-associated molecular patterns 
(PAMP) and include bacterial lipopolysaccharide, peptidoglycan, mannans, and bacterial 
DNA.  The complimentary receptors on human cells of the innate system are called 
pattern-recognition receptors (PRR).  The effector responses of the innate system are 
therefore non-specific and available immediately irrespective of the number of times the 
same pathogen is encountered (37). 
 
The specificity of the receptors of the acquired response is generated by somatic gene 
rearrangement, which produces a vast repertoire of antigen specific receptors, about 
1014-1018x106, enabling the recognition of a wider range of antigens and increased 
ability to detect pathogens.  After encountering and recognizing pathogenic antigen 
presented by antigen presenting cells (APC), naïve (antigen inexperienced) lymphocytes 
generate effector cells by clonal expansion and differentiation, which requires two to 
three weeks.  This process also produces memory cells, which allows a more rapid 
response on subsequent re-exposure to the same antigen (38). 
 
Immune recognition and uptake of MTB by the phagocytic cells of the innate system 
leads to the initiation of the inflammatory response as well as the induction and activation 
of the acquired response.  Phagocytosis is mediated by binding of PAMP to endocytic 
PRR including the macrophage mannose receptor, complement receptors, scavenger 
receptors as well as the dendritic cell-specific intercellular adhesion molecule-3-grabbing 
non-intergrin (DC-SIGN) receptor, Figure 3 (39).   
 
In the immunocompetent host, this process takes place within hours after the inhalation of 
MTB, via the interaction of the innate receptors on macrophages and DC and various 
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Figure 3.  Recognition of MTB by the innate immune response, adapted from 
Eun- Kyeong Jo (39). 
 
Phagocytosis induces innate killing mechanisms, which include phagosomal acidification 
and fusion with lysosomes containing microbicidal enzymes, proteins and peptides that 
are released into the phagosome.  Nitric Oxide (NO), a toxic anti-mycobacterial product, 
is produced by the induction of nitric oxide synthase (iNOS) in activated macrophages.  
Another mechanism is the respiratory burst, which generates toxic products via the 
generation of superoxide anion (O2-), which is further converted to hydrogen peroxide 
(H2O2).  H2O2 is further processed into additional toxic chemicals including the hydroxyl 
radical (OH).  Collectively these toxic products are referred to as reactive oxygen 
intermediates (ROI) (40).   
 
However, MTB has evolved strategies to overcome and inhibit these macrophage effector 
functions and survives within the phagosomes of infected macrophages via mechanisms 
that block phagosome acidification as well as mechanisms that avoid oxidative killing 
(41).    
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The Toll like receptors (TLRs) are mammalian homologues of the Drosophila Toll 
protein, which was first identified as a component of the embryonic development of the 
fly and later as a key component of the immune response of the adult fly .  At least 10 
mammalian TLRs have been identified to date.  Binding of TLRs, present on the surface 
of macrophages and DC, to various mycobacterial components, induces a common 
signaling transduction pathway.  This takes place via the cytosolic adaptor protein, 
myeloid differentiation protein 88 (Myd 88), and leads to the activation of transcription 
factors for the Nuclear Factor KB (NF-KB) family, which moves into the nucleus (37).   
 
This results in the macrophage and DC expression of cytokines, chemokines and co-
stimulatory molecules required to initiate and activate components of the acquired 
immune response, as well as innate killing mechanisms.   
Figure 4 presents a diagrammatic summary of key innate generated molecules and 
cytokines that contribute to the initiation and activation of acquired immune responses, 





Figure 4: Immune activation following MTB/phagocyte binding, adapted from van 
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Within the APC, degradation of phagocytosed MTB antigens into peptides, takes place 
via the action of proteases inside endosomes.  Fusion of the endosomes with the Golgi 
apparatus allows the binding of the peptides to newly synthesised Major 
Histocampatibility (MHC) class II molecules, which are retained in the Golgi apparatus.  
The MHC class II-peptide complex is transported to the surface of the APC, which 
migrates to the regional lymph nodes to present antigen to T cells.  Newly synthesised 
MHC class I molecules are retained within the Endoplasmic Reticulum (ER).  Peptides 
formed from the degradation of antigens present in the cell cytoplasm are transported into 
the ER where they bind to MHC class I molecules, forming MHC class I-peptide 
complexes, which are transported to the cell surface to facilitate antigen presentation to T 
lymphocytes (T cells) (42). 
 
MTB antigens confined in phagosomes are secluded from transport to the ER and 
classical MHC class I binding.  However, recent studies have revealed that apoptosis of   
MTB infected APC, allows the delivery of MTB antigen to non-infected bystander APC, 
via apoptic vesicles, in a process referred to as cross priming.  This process subsequently 
allows the binding of MTB peptides to MHC class I molecules, and subsequent 
presentation to T cells (43)(44). 
 
In the lymph nodes, naïve T cells (antigen inexperienced) are stimulated via interaction 
with the MHC-peptide complex and co-stimulatory signals provided by the expression of 
Cluster of differentiation (CD) molecule 80 and CD86 on the APC.  CD4+ and CD8+ T 
cells bind to MHC-peptide complexes via the αβ T cell Receptor Complex (TCR).  Co-
stimulation takes place via the binding of the CD28 molecule expressed on the T cell 
surface to the co-stimulatory molecules expressed on the surface of the APC.  Stimulation 
results in proliferation by clonal expansion and differentiation into antigen specific 
effector cells, which migrate to the site of infection and exert effector function (38).   
 
CD4+ T cells function as helper T cells (Th) via the secretion of cytokines (45).  CD4+ T 
cells are classically differentiated into type 1 helper T cells  (Th1) and type 2 helper T 
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Th1 CD4+ T cells secrete the cytokines, tumour necrosis factor (TNF), interferon gamma 
(IFN-γ), and interleukin (IL)- 2.  IL-10 and Transforming Growth Factor β (TGFβ) are 
regulatory cytokines also secreted by T cells.  Th2 CD4+ T cells secrete IL-4, IL-5, and 
IL-13 (46).  A novel group of IL-17 secreting, Th17 T cells have been identified recently 
(47).   
 
Activated CD4+ T cells express CD40 ligand (CD40L), which binds to CD40 expressed 
on B cells and activates antibody production (48).  DC and macrophages also express 
CD40 (49).  Binding to CD40L stimulates the secretion of TNF, IL-12, MHC molecules, 
as well as co-stimulatory molecules (50)(51).  
 
CD8+ T cells have a cytotoxic function, and kill infected cells via activation of enzyme-
mediated apoptosis, as well as through their production of cytotoxic mediators such as 
granzyme, perforin, and granulysin (52).  
 
NK cells do not express an antigen specific TCR and use non-specific receptors to 
identify and kill infected cells in an innate cytotoxic manner.  NK cells also secrete IFN-γ 
and are considered to be an important source of IFN-γ in early   infection (53).  Natural 
killer T cells (NKT) bind to glycolipid antigen via CD1 antigen presentation, resulting in 
the secretion of IL-4 and IFN-γ (53). 
 
Studies have revealed the involvement of various T cell subtypes and cytokines in the 
immune response to MTB (54).  CD4+ IFN-γ secreting T cells have been shown to be 
essential for the maintenance of a protective response to MTB in mice and humans.  
CD4+ T cell knockout mice are unable to control MTB infection despite the presence of 
large volumes of IFN-γ (55).  Deficiency of the IFN-γ receptor (IFN-γR) in humans is 
associated with an increased susceptibility to non-tuberculous mycobacterial infection 
(56).  The role of CD4+ T cells in the protective response to MTB in humans is further 
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IFN-γ activates killing mechanisms in infected macrophages and regulates the expression 
of MHC and co-stimulatory molecules, which is essential for the stimulation and 
activation of the acquired immune response (57).  Despite the established role of IFN-γ in 
the protective response to MTB, studies investigating the IFN-γ response as a marker of 
protection found a lack of correlation, stressing the need for identification of more 
reliable correlates (58)(59).   
 
TNF is involved in the induction of the inflammatory response (60).  The role of TNF in 
the induction of MTB specific T cells and activation of innate mechanisms is best 
demonstrated by the reactivation of TB in people with LTBI, who had received anti-TNF 
(Infliximab) therapy for autoimmune disease (61). 
 
IL-10 has been associated with suppression of macrophage function (60).  The over 
expression of IL-10 in mice has been associated with the reactivation of chronic 
pulmonary TB (62).  In humans, the expression of IL-10 in response to Purified Protein 
Derivative (PPD) re-stimulation was associated with anergy and the absence of IFN-γ 
secretion (63). 
 
IL-2 induces T cell proliferation (60).  A study that investigated the effect of HIV 
infection on the expression of IL-2 and the IL-2- receptor-α (IL-2-R-α) found that TB in 
HIV infected people was associated with substantially reduced serum IL2-R-α levels, 
compared to HIV uninfected people with TB (64).  
 
The cytotoxic effect of CD8+ T cells has been demonstrated in mice in which the 
knockout of β2-microglobulin resulted in a high susceptibility to MTB.  This was 
probably due to iron overload (65).  In humans, the presence of IFN-γ secreting, antigen 
specific CD8+ T cells have been shown to participate in the maintenance of LTBI in 
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In studies performed by Vankayalapati et al, NK cells were shown to regulate CD8+ T 
cells by contributing to IFN-γ secretion and priming of CD8+ T cells to lyse MTB 
infected monocytes and alveolar macrophages (67).   
 
A recent study by Sutherland et al, 2009, documents a significant decrease in the 
percentage of B and NKT cells in adults with active TB as compared to their LTBI house 
hold contacts (68).   
 
T cells expressing a γδTCR have been shown to secrete IFN-γ and lyse MTB infected 
macrophages (69).  They have also been associated with the restriction of mycobacterial 
growth (70). 
 
The immune response to MTB infection, which can result in active TB or LTBI, is 
determined by the interaction of a wide range of MTB molecules and cells of both the 
innate and acquired immune response.  The final outcome is a reflection of the balance 
created as a result of these interactions.  The development of new vaccines and the 
identification of reliable correlates of immune protection against MTB infection will be 
influenced by the unraveling of these complex interactions (54). 
 
1.3.  Measuring the MTB specific immune response 
 
1.3.1.  Techniques 
Antigen stimulated whole blood assays have allowed secreted protein and messenger 
ribonucleic acid (mRNA) levels to be measured by the use of techniques such as the 
enzyme linked immunosorbent assay (ELISA) and the polymerase chain reaction (PCR), 
which allows the detection of bioactive protein as well as very low levels of message.  
Lymphocyte proliferation assays (LPAs) are suitable for analysis of large numbers of 
samples; however, they do not provide information on the phenotype of antigen specific 
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Achieving the objectives of this dissertation, as presented in Section 1.4, required the use 
of techniques that allowed qualitative and quantitative analyses at the level of the single 
cell, as well as the detection of antigen specific cytokine secreting cells that were present 
in low numbers.   
 
Another relevant consideration was that the chosen techniques could be efficiently 
performed within the scope of the environment in which the study would be taking place.  
Thus, Flow Cytometry in conjunction with intracellular cytokine staining and the ezyme-
linked immunospot (ELISpot) technique were the chosen assays.  
 
1.3.1.1.  Flow cytometry and intracellular cytokine staining 
Immunophenotyping requires the description of molecules expressed on the cell surface, 
as well as inside the cell.  Flow cytometry enables the simultaneous measurement of 
multiple cell surface antigens at a single cell level.   
 
It also enables the measurement of the proportion of specific subtypes within a 
population of cells and the absolute number of cells in a volume of whole blood.  Flow 
cytometry in conjunction with fluorescent conjugated monoclonal antibodies (mAbs) are 
used to characterise distinct cell types and activation states (73).   
 
The basic principle of a flow cytometer is the measurement of scattered and fluorescent 
light emitted as cells pass through the intersection of a light source, via a fluid stream.  
Laser beams at specific wavelengths provide the light source.  Scattered light is derived 
from the size and granularity of cells and fluorescent light is derived from the 
fluorochromes conjugated to mAbs (73)(74)(75). 
 
Cells for immunophenotyping are prepared by incubation with fluorochrome-labeled 
mAbs.  The cell suspension is drawn up into a sample port on the flow cytometer and 
injected into a stream of isotonic saline solution to form a laminar flow.  The containment 
of the sample stream by the carrier stream creates a hydrodynamic focus that allows the 
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This process takes place inside a flow cell (FL).  As the cells pass through the light 
source, detectors collect the scattered and fluorescent light (73)(74)(75). 
 
The detector collecting forward scatter (FSC) is placed directly in the path of the light 
source.  The remaining side scatter (SSC), and fluorescent light is collected at 90˚ from 
the light source, and is directed to the fluorescent detectors via fiber optic cables.  Optical 
filters direct specific wavelengths of light to the appropriate filters.  The detectors are 
photomultiplier tubes (PMT) that convert electrical signal to a voltage pulse.  The voltage 
output is quantified and digitised by a computer system (73)(74)(75). 
 
The size of the voltage output is determined by the amount of light reaching the PMT as 
well as the voltage setting of the PMT, and therefore optimisation of the voltage setting is 
an important aspect of machine setup.   
 
Each fluorescent detector is setup to collect light from a particular fluorochrome, 
however light from other fluorochromes may also be detected.  Fluorescent spillover is 
referred to as spectral overlap and requires removal in a process referred to as fluorescent 
compensation.  The separation of small less granular lymphocytes from other leukocytes 
is achieved on the basis that larger cells scatter more light, in a process called scatter 
gating (73)(74)(75). 
 
The analysis of flow cytometry generated data starts with the assessment of the quality of 
the lymphocyte gate as well as the establishment of negative and positive analysis regions 
using isotype controls.  Figure 5 presents the basic design of a flow cytometer set up 
(73). 
 
The use of anti-cytokine antibodies in a staining technique that allows the intracellular 
detection of cytokines and cell surface molecules, without the separation of cells, has 
greatly enhanced the use of flow cytometry to determine immunophenotype in human 















Figure 5.  Schematic diagram of a typical flow cytometer set up, adapted from 
Micha Rahman (74). 
 
1.3.1.2.  Detecting antigen specific T cells by ELISpot 
In 1983, the ELISpot was described as an alternative for the detection of antibody 
secreting cells (80).  The use of nitrocellulose membranes and anti-cytokine mAbs 
modified the assay for the detection of antigen specific T cells.  The assay was shown to 
have an estimated sensitivity of detecting 50 or fewer antigen specific T cells per 106 
lymphocytes.  This represents an increased sensitivity of at least 1 log10 more than the 
LPA (71).  
 
Cytokine secreting T cells are detected as coloured spots via staining with an enzyme 
linked anti-cytokine mAb.  The spots can be enumerated with the naked eye, however the 
development of ELISpot readers have automated the enumeration of spot forming cells 
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The technique has been successfully used in the detection of antigen specific T cells in a 





Figure 6.  Diagrammatic presentation of the ELISpot technique adapted from 
Julian K. Hickling (71). 
 
1.3.2.  MTB specific antigens 
The detection of prior sensitisation to MTB has traditionally been achieved via the 
tuberculin skin test (TST).  The TST is performed by the intradermal administration of 
PPD.  The induration of a delayed-type hypersensitivity reaction is measured 48-72 hours 
later.  A positive skin test response may be an indication of LTBI, however PPD is a 
crude mixture of MTB proteins, which are shared amongst MTB, M. Bovis BCG and 
many other environmental mycobacteria.  False positive TST results could therefore 
develop as a result of cross reactivity to prior BCG vaccination and exposure to 
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The search for non cross reactive antigens and the sequencing of the MTB genome have 
revealed MTB specific antigens that are potential candidates in the development of new 
vaccines, and the search for reliable correlates of immune protection.  Thus it is necessary 
to investigate the ability of these antigens to induce a measurable T cell response as well 
as to determine the quality of the response to these novel antigens in people who are 
already sensitised by MTB (86)(87). 
 
Early-secretory antigenic target-6 (ESAT-6), and culture filtrate protein-10 (CFP-10), are 
encoded by the MTB genomic segment, region of difference-1 (RD1). 
This region is absent from the BCG vaccine and most environmental mycobacteria (88).  
ESAT-6 and CFP-10, in conjunction with ELISA and ELISPOT, have been shown to be 
immunodominant targets of the acquired immune response to MTB.  Both antigens are 
used in approved diagnostic test kits to detect the existence of an IFN-γ secreting T cell 
response to TB antigens as a measure of prior sensitisation to MTB (89)(90)(91). 
 
The esat-6 gene (Esx) family has revealed a number of immunogenic proteins that are 
recognised by the acquired immune response in both humans and cattle.  M. bovis and 
MTB share genetic homology of 99.9% (92).  Rv3109c (TB10.3), a member of the Esx 
family, was shown to induce a significant IFN-γ response in BCG vaccinated cattle (93).   
 
Other MTB antigens investigated for immunogenic ability include Rv2031c (ACR1) and 
Rv0251c (ACR2).  ACR1 and ACR2 are both members of the α-crystallin (ACR) family 
of molecular chaperones.  ACR1 has been associated with the persistence of bacteria in a 
non-replicating state.  The infection of mice with a mutant ACR2 gene has been 
associated with a reduction in the recruitment of T cells and macrophages to the lungs of 
mice infected with MTB (94)(95).   
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1.3.3.  Measuring T cell memory to MTB infection 
The identification of molecules involved in the cellular activity of the immune response 
has facilitated the identification of T cell phenotype and function (36).   
 
Naïve T cells do not migrate (home) to peripheral tissues.  Following homing from the 
thymus to the lymph nodes, naïve T cells proliferate and differentiate into effector T cells 
capable of homing to peripheral tissues.  Effector T cells are mostly short-lived; although 
a few antigen experienced cells remain long-lived and give rise to a population of 
memory T cells.  Memory T cells are differentiated on their migratory ability.  Central 
memory T cells (TCM) preferentially migrate to the lymphoid tissues whereas effector 
memory T cells (TEM) migrate to peripheral tissues (96)(97).  CD45 is a phosphatase 
enzyme involved in the activation of T cells.  The CD45 receptor (CD45R) occurs in 
different isoforms.  The isoforms, CD45RA and CD45RO differentiate naïve from 
memory cells respectively (98).  The CD45RA molecule can also be used in the  
 
β-Chemokines (CC), are chemoattractant molecules that induce the migration of 
lymphocytes.  Selectins are molecules that facilitate the movement of cells (38).  The 
homing of naïve and TCM cells to lymph nodes are assisted by the expression of 
chemokine receptor (CCR) 7 and the receptor for L- selectin (CD62L) (97).  The homing 
of TEM to sites of infection in peripheral tissues is assisted by the expression of CCR5.  
The expression of CCR5 can differentiate TEM, from TCM.  Terminally differentiated 
effector T cells do not require co-stimulation on activation.  The lack of expression of the 
co-stimulatory molecule CD27 differentiates terminally differentiated effectors from 
naïve cells, TCM and TEM (99).  Terminally differentiated effector CD4+ T cells are also 
associated with a lack of CCR7 expression and re-expression of the CD45RA molecule 
(99).   
 
The phenotype of T cells can be identified on the basis of expression, or lack of 
expression, of these and other molecules.  Table 1 presents a scheme used in the 















Table 1.  Scheme used to characterise CD4+ T cell subtypes by phenotype and function, 
adapted from Elisabeth Amyes et al (99), and Frederica Sallusto et al (97). 
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1.3.4.  The effect of HIV on the immune response to MTB infection 
HIV gains entry to cells via CCR5 and α-chemokine receptor (CXCR) 4, which are 
expressed on activated CD4 T cells.  HIV also uses the CD4 molecule.  HIV infection 
and replication leads to excessive cell death, alterations in antigen presentation, 
alterations in T cell migration patterns and damage of thymic function (100)(101).  The 
acute phase of the HIV infection is associated with a profound decline in the CCR5+ 
CD4+ T cells, which represent a memory and effector T cell subset, and this depletion is 
maintained throughout all stages of the disease (102)(103).   
 
HIV infection causes a progressive loss and decline in CD4+ T cell numbers which is 
emphasised by the increase in risk of developing TB to 10% per annum in HIV infected 
people, as compared to 10% per life time in HIV uninfected people (20)(23)(6)(7)(8).   
Antiretroviral treatment acts by blocking viral entry to cells and preventing replication, 
which decreases infection of CD4+ T cells by the virus and has been associated with an 














Combination antiretroviral therapy (cART) has been shown to reduce the incidence of 
tuberculosis.  A study performed in Cape Town, and others, showed that cART was 
associated with a reduction in the incidence of TB, in HIV-TB co-infected people, of 
more than 80% (104)(105)(106)(107)(108).  Studies performed in the late 1990’s 
document the restoration of immune function during antiretroviral therapy.  This was 
largely due to the restoration of CD4+ memory T cells by 4 weeks after treatment, which 
was sustained up to 12 months, as well as the restoration of naive CD4+ T cells by 4 
months after antiretroviral therapy, also sustained up to 12 months of therapy 
(109)(110)(111)(112)(113).   
 
Antiretroviral therapy has no known anti-mycobacterial activity, which leads to the 
question of  ‘How is the protection mediated’.  Detailed in vitro analysis of MTB antigen 
specific T cell subsets that expand during cART in persons with latent tuberculosis will 
contribute toward a better understanding of the nature of the MTB specific memory 
response as well as contribute to the need for the identification of more reliable correlates 
of protection.  This study was therefore performed to investigate the hypothesis of the 
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1.4.  Hypothesis of the study 
 
MTB specific CD4+ T cell subsets that expand during cART in people with LTBI, 
mediate protection.   
 
1.5.  Aim of the study 
 
To characterise, in a longitudinal analysis, MTB specific T cell subsets that expand 
during cART, in order to determine protective mechanisms in TB and thus contribute to 
the identification of novel correlates of protection. 
 
1.6.  Objectives of the study 
 
1. To determine the phenotype of the CD4+ T cell subsets, as well as other cell 
types, that respond to stimulation by MTB specific antigens, particularly the 
CD4+ memory subtypes, from the time of starting cART, over a period of 48 
weeks using flow cytometry in conjunction with intracellular cytokine staining. 
 
2. To quantitate IFN-γ production in response to a range of MTB specific antigens, 
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Chapter 2.  Materials and Methods 
 
All tissue culture procedures were performed using strict aseptic techniques, under sterile 
conditions. 
All manipulations with unfixed cells took place inside Class II bio-safety cabinets. 
All reagents were used and stored according to the manufacturers instructions. 
All laboratory equipment was regularly serviced according to the manufacturers 
instructions and temperature ranges were monitored on a daily basis. 
All waste generated were disposed of according to the bio-hazardous waste disposal 
protocols of the University of Cape Town.   
Materials used, manufacturers details and product numbers are presented in the form of 
tables at the end of each section. 
 
2.1.  Study site and participants 
The study received approval from the Research Ethics Committee of the University of 
Cape Town: REC REF 336/2004.  Study participants were identified and recruited on 
enrollment into the antiretroviral treatment program at GF Jooste Hospital, Manenberg, 
and Cape Town whose catchment area includes the townships of Khayelitsha, Gugulethu, 
and Nyanga.  Eligibility was based on a CD4 count of 200 cells/µl or less, and/or WHO 
stage 4 disease according to South African national guidelines.  Antiretroviral treatment 
prescribed was the standard first line combination of stavudine (d4T), lamivudine (3TC) 
and either nevirapine (NVP) or efavirenz (EFZ).  
 
 All participants provided informed consent and a copy of the consent form was given to 
each participant.  Exclusion criteria were age under 18 years, active TB, and pregnancy.  
A total of 28 study participants were recruited and enrolled between April 2005 and 
September 2007.  The study baseline was the day on which cART started (d0) and follow 
up time-points were at 2,4,12,24,36 and 48 weeks into cART.  
A 30 ml sodium heparinised whole blood sample was aseptically obtained via 
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A 5 ml clotted blood sample for serum separation was also obtained.  All blood samples 
were transported to the laboratory site and processed according to the study’s 
experimental standard operating procedures (SOP) within 4 hours of collection. 
 
Twelve HIV uninfected, MTB sensitised adults (as determined by either a positive 
tuberculin skin test or a positive response to either ESAT-6 or CFP-10 in the ELISpot 
assay) were recruited from the same community (5 females, 7 males, median age 25 
years) and served as controls in parts of the study.  
 
2.2.  Isolation and cryopreservation of the peripheral blood mononuclear cells   
        (PBMC) and Serum 
 
2.2.1.  Method 
PBMC were isolated from the heparinised whole blood sample, drawn at each study time 
point, using density gradient separation (114).  Whole heparinised blood was diluted 1:2 
with sterile phosphate-buffered saline (PBS) to a total volume of 30 mls, in a sterile 50 
ml centrifuge tube.  The diluted whole blood was aspirated and gently layered onto 10 
mls of Ficoll-Paque in a 50 ml centrifuge tube.  The layered, diluted whole blood was 
centrifuged at 700g for 20 minutes with the centrifuge brakes off, so as not to disturb the 
cell layers formed.  The layer of PBMC was carefully aspirated and transferred to a new 
50 ml tube containing 10 mls PBS.  After aspiration and transfer of the PBMC, more PBS 
was added so that the total volume equaled 40 mls.  
 
The PBMC were pelleted by centrifugation at 600g for 10 minutes, with the centrifuge 
brakes on.  The pellet was re-suspended and washed twice, in 10 ml RPMI 1640 culture 
medium containing 10% Heat-Inactivated Foetal Calf Serum (HI FCS), that was filtered 
through a 0.22 µm low protein-binding filter, prior to use.  
 
 A 20-µl aliquot of the washed and re-suspended PBMC was used to perform a cell count, 
using 0.4% Trypan blue dye and a disposable cell counting chamber (115).  Cells that 
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The following formula was used to determine the number of cells per ml: 
 
Count/ml =    total count      x 104 x sample dilution  
  Number of 4 x 4 grids counted 
   (1 grid equals 16 squares) 
 
Freshly isolated PBMC were used for the flow cytometry assay.  Remaining cells were 
re-suspended at a concentration of 10x106 cells/ml in a cell freezing solution consisting 
of 45% RPMI, 45% HI FCS and 10% Dimethyl Sulfoxide (DMSO) (116).  This cell 
suspension was transferred to 1.8 ml cryotubes.  The cryotubes were placed into a 
Nalgene Mr. Frosty freezing apparatus, and frozen at -80˚C overnight (117).  The next 
day the frozen cells were transferred to the vapour phase of a liquid nitrogen tank, where 
they were stored for use in the ELISpot assay.  Serum was isolated from the 5ml clotted 
blood sample by centrifugation at 3000g for 10 minutes.  The serum was aspirated and 
transferred to 1.8 ml cryotubes.  All sera were stored at -80˚C for future use.   
2.2.2.  Materials and reagents 
Table 2.  Materials and reagents used in the isolation and cryopreservation of PBMC. 
Product Supplier and product number (#) 
10 ml BD Vacutainer®, glass Sodium 
Heparin, plasma tube 
BD Diagnostics, 1 Becton Drive 
Franklin Lakes, NJ USA 07417  
#368480 
5 ml BD Vacutainer® SST II Plus, plastic 
serum tube 
BD Diagnostics, 1 Becton Drive 
Franklin Lakes, NJ USA 07417  
#367955 
BD Falcon™ 50ml centrifuge tubes  Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 
#352070 
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Ficoll-Paque™ PLUS GE Healthcare Biosciences, Sweden 
#17-1440-03 
RPMI 1640 Sigma-Aldrich, South Africa 
#R8758 
Fetal calf serum, endotoxin free Delta Bioproducts, Highveld Biological,  
Lyndhurst, South Africa 
#14-501-BI 
500µl Filter System 0.22um CA 
(Cellulose Acetate), Low Protein Binding 
membrane 
Corning, NY 14831, USA 
#430769 
Dimethyl Sulfoxide Sigma-Aldrich, South Africa 
#D5879 
Trypan blue 0.4% Sigma-Aldrich, South Africa 
#T8154 
Fast-Read 102, disposable counting 
chambers 
Immune Systems LTD, United Kingdom 
#BVS100 
NUNC™, 1.8ml Cryotubes, sterile, 
external thread 
Thermo Fisher Scientific, Roskilde, 
Denmark 
#375418 
5100 Cryo 1˚C Freezing Container, “Mr. 
Frosty” 
Nalgene ® Labware, Thermo Fisher 
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2.3.  The Flow Cytometry Assay 
 
The flow cytometry assay was used to determine PBMC phenotype and cytokine 
secretion.  The in vitro re-stimulation and staining of molecules for surface phenotyping, 
and intracellular cytokine expression, were performed consecutively on the same sample 
aliquot (118)(119).   
2.3.1.  Method 
2.3.1.1.  Re-stimulation and surface phenotype staining 
The staining and re-stimulation of the cells were performed in a round-bottomed 96 well 
micro-titre plate.  Freshly isolated PBMC were inoculated into duplicate wells on a 
micro-titre plate at a minimum concentration of 200 000 cells per well and a maximum of 
500 000 cells per well, depending on availability, in a volume of 200 µl RPMI 1640 
culture medium containing 10% HI FCS.  PPD was used as a stimulant to determine the 
MTB specific memory responses, at a final concentration of 10 µg/ml.  Co-stimulating 
molecules were not used (120).  
 
The superantigen, Staphylococcal Enterotoxin B (SEB), was used as a stimulant in the 
positive control wells, at a final concentration of 5 µg/ml (121).  No stimulant was added 
to the negative control wells.  After addition of the stimulant, the cells were incubated for 
2hrs at 37˚C with 5% CO2, to allow antigen presentation to take place.  The plate was 
removed from the incubator after 2hrs and the cytokine secretion inhibitor, Brefeldin A 
(BFA), was added to each well intended for intracellular cytokine staining (118)(119).  
The final concentration of BFA was 5 µg/ml.  The cells were returned to incubation at 
37˚C in 5% CO2 for a further 18hrs, following which, the cells were pelleted by 
centrifugation at 1200 rotations per minute (rpm) for 5 minutes. 
  
The supernatant was gently removed, using a multi-channel pipette, and the pellet 
loosened by gently vortexing the closed plate.  The cells were then washed with 
Fluorescence-activated cell sorting (FACS) wash buffer (PBS, 2% HI-FCS and 0.1% 
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 Surface staining was performed using predetermined, optimal volumes of fluorescent 
conjugated mAbs at 4˚C for 20 minutes.  After staining, the cells were washed in FACS 
buffer, 100 µl per well, re-pelleted, and loosened as described.  The cells used for surface 
staining only were then re-suspended in FACS FIX buffer (PBS/2%HI- FCS/0.1% NaN3 
and 1.6% paraformaldehyde), 200 µl per well.  These cells were transferred to 5 ml round 
bottomed polystyrene tubes, and stored at 4˚C in the dark, until the rest of the protocol 
was completed.   
 
2.3.1.2.  Intracellular cytokine staining 
The cells intended for intracellular cytokine staining were re-suspended in 100 µl per 
well of BD Cytofix/Cytoperm™ solution for 20 minutes at 4˚C, to allow for fixation and 
permeabilisation of the cell membrane.  The cells were then washed in 100 µl per well of  
1x BD Perm/Wash™ buffer, re-pelleted and loosened as described.  Intracellular staining 
was performed using predetermined optimal concentrations of fluorescent conjugated 
monoclonal antibodies, for 30 minutes at 4˚C.  Thereafter a final wash was performed in 
100 µl per well of 1x BD Perm/Wash™ buffer.  The cells were re-pelleted and loosened 
as described, and were re-suspended in 200 µl per well of FACS wash buffer.  All stained 
samples were acquired immediately on a BD FACSCaliburTM   Flow Cytometer (Serial 
number E3530), using the BD CellquestTM Pro Programme.  A total of 150 000 events, 
within the lymphocyte gate, were acquired per tube.  Results were analysed using Flowjo 
Cytometry Analysis software, Version 7 (Tree star Inc Stanford University, Flowjo 
Africa Scheme). 
 
The combination of fluorescent conjugated mAbs was restricted to the use of four 
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Table 3.  Combinations of fluorescent conjugated monoclonal antibodies used to  


























1 PPD anti-IFN-γ anti-CD4 anti-CD27 anti-CD62L 
2 PPD anti-IFN-γ anti-CD4 anti-CD27 anti-CCR5 
3 PPD anti-IFN-γ anti-CD4 anti-CD27 anti-CCR7 
4 PPD anti-IFN-γ anti-CD4 anti-CD27 anti-CD45RA 
5 PPD anti-IFN-γ anti-CD4 anti-CD69 anti-CD45RO 
6 PPD anti-TNF anti-CD4 anti-IL-2 anti-IL-10 
7 PPD anti-IFN-γ anti-CD8 anti-CD27 anti-CD62L 
8 PPD anti-CD3 anti-CD4 anti-CD25 anti-IL-10 
9 PPD anti-CD3 anti-CD19 anti-CD69 anti-CD56 
 
2.3.2.  Determination of optimal antibody concentrations  
Using the method described in Section 2.3.1, antibody titrations were performed in order 
to determine the concentration of antibody that would result in maximum positive 
staining and minimum non-specific staining under the conditions of the study method 
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Table 4.  Optimal volumes of fluorescent conjugated monoclonal antibodies used.  
Fluorescent conjugated monoclonal antibody used Volume per well 
All surface phenotype antibodies 3 µl 
anti-IFN-γ 0.5 µl 
anti-TNF 3 µl 
anti-IL-10 5 µl 
anti-IL-2 3 µl 
 
2.3.3.  Validation of the flow cytometry assay parameters 
This section describes the optimisation of the Flow Cytometer instrument settings, 
sensitivity, and fluorescent compensation.  It includes a description of the controls used 
to adjust for auto-fluorescence, non-specific background staining and the controls used to 
study the PBMC response to in vitro re-stimulation.  All the PBMC controls were 
prepared using the study methods described in Sections 2.3.1 and 2.3.2.  Parallel 
experiments were performed when preparing the PBMC controls, one using un-
stimulated PBMC as well as PPD re-stimulated PBMC, in order to identify any 
component of the methods and reagents that could contribute to non-specific 
fluorescence. 
 
2.3.3.1.  Instrument optimization  
The Flow Cytometer instrument settings, sensitivity and fluorescent compensation 
settings were optimised and monitored on a routine basis using the BD CaliBRITETM 
bead system in conjunction with FACSCompTM   software, according to the 
manufacturer’s instructions (119).  The BD CaliBRITETM bead system uses two tubes, 
one containing an unlabeled bead suspension and another containing a mixture of 
fluorescent labeled beads, each present in equal amounts.   
 
The software positions the unlabeled bead suspension at predetermined target positions, 
following which the individual PMT voltages are adjusted until the mean values 
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The software programme then uses the mixed-bead suspension to achieve optimal 
fluorescent compensation following which it performs an instrument sensitivity test.   
The software generates a visual report for each test performed.  The routinely generated 
reports were also used to monitor the stability of the instrument over time.  
 
When any failed parameters or alterations in the stability of the instrument were detected, 
the required procedures and interventions, as recommended by the manufacturers, were 
performed and the above measures repeated until acceptable reports were generated.  
When all the parameters were passed, the generated instrument sensitivity, PMT voltages 
and fluorescent compensation settings were validated and adjusted for use on the study 
PBMC, as described in the following section. 
 
2.3.3.2.  PBMC controls 
The beads used in the BD CaliBRITETM bead system possess optical properties different 
to that of human cells, thus PMBC controls, as shown in Table 5, were prepared, in order 
to validate and optimize the settings generated as described in Section 2.3.2.1, for the 
purpose of analysing the study PBMC (122,123).  To ensure that the study PBMC were 
placed within the gates and analysis regions of the various plots formatted, the software 
generated PMT voltage settings were validated and optimised first, and the subsequent 
settings saved.  The saved settings were then applied to the validation and optimisation  
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Unstained Nil     All time 
points 
Unstained PPD     Monthly 
Isotype 1 Nil    anti-IgG1   Monthly 
Isotype 1 PPD   anti-IgG1   Monthly 
Isotype 2 Nil    anti-IgG1   Monthly 
Isotype 2 PPD    anti-IgG1   Monthly 
Isotype 3 Nil    anti-IgG2   Monthly 
Isotype 3 PPD    anti-IgG2   Monthly 
Isotype 4 Nil anti-IgG1      Monthly 
Isotype 4 PPD anti-IgG1      Monthly 
Isotype 5 Nil  anti-IgG2     Monthly 
Isotype 5 PPD  anti-IgG2     Monthly 




























Following validation of the unstimulated PBMC controls the re-stimulated PBMC 
controls were used to verify that re-stimulation did not alter the position of the study 
PBMC.  The unstained PBMC control was used to optimize the resolution of the PBMC 
and lymphocyte populations, evaluate possible auto-fluorescence as well as to confirm 
that the unstained, un-stimulated lymphocyte population was placed in the correct 
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The isotype-matched controls were then used to evaluate possible non-specific staining 
and to set the negative and positive analysis regions, using quadrant markers (123).   
 
The four colour stained control was used to determine that appropriate separation 
between the negative and positive analyses regions were achieved and to adjust the 
fluorescent compensation settings as required (123).  SEB was used as a stimulant in the 
positive control to validate cytokine release (121).  The final instrument settings, 
compensation settings, gates, negative and positive analysis regions were saved and 
applied to the analysis of the study PBMC. 
 
2.3.4.  Gating strategies 
2.3.4.1.  Acquisition of data 
The BD CellquestTM Pro Programme was used to design an acquisition template.  Scatter 
dot plots were chosen to display the data acquired.  The acquisition of data was restricted 
to the CD4+, CD8+, CD3+ , and CD3- T cells, which were identified using the FSC and 
SSC parameters, and isolated by drawing a gating around it.  These gates were set to 
acquire all positive events.  The template was designed to display the acquisition of the 
gated T cells and subsets using combinations of the SSC, FL1, FL2, FL3, and FL4 
parameters.  The template was applied during the acquisition of the control PBMC as 
well as the study PBMC, in order to monitor the quality of the events displayed. 
 
2.3.4.2.  Analyses of data 
The gating strategies used to analyse the subsets within the T cell populations are shown 
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2.3.5.  Materials and Reagents 
Table 6.  Material and reagents used in the Flow Cytometry Assay. 
 
Product Supplier and product number (#) 
Costar round bottomed 96 well micro-titre  
plates 
Corning Incorporated, Corning, New York 
#14831 
RPMI 1640 See Table 2 
Tuberculin Purified Protein Derivative 
(PPD) 
Statens Serum Institut, DK-2300, 
Copenhagen S, Denmark #2391 
Epstein Barr Virus infected cell extract 
East Coast Bio, Inc, USA 
East Coast Bio, Inc, USA 
Staphylococcal Enterotoxin B  Sigma-Aldrich, South Africa 
#S-4881 
Brefeldin A Sigma-Aldrich, South Africa 
#B-7651 
Phosphate Buffered Saline See Table 2 
Fetal calf serum, endotoxin free See Table 2 
Sodium Azide Sigma-Aldrich, South Africa 
#S-2002 
Paraformaldehyde, 16% w/v aqueous 
solution, methanol free 
Alfa Aesar, The Right Chemicals, 30 Bond 
Street, Ward Hill, MA 01835, 800-343-
0660 
#CAS-#30525-89-4 
BD Falcon™  
Polystyrene round bottomed tubes, 5ml, 
12x75mm style 
Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 
#352054 
BD Cytofix/Cytoperm™  Becton Dickson Biosciences, Pharmingen, 
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BD Perm/Wash™  Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 
#51-2091KZ 
BD CaliBRITETM 3 three-color-kit Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 
#340486 
BD CaliBRITETM APC Beads 
 
Becton Dickson Biosciences, Pharmingen, 




Table 7.  BD Pharmingen™ fluorescent conjugated antibodies used in the Flow  
     Cytometry Assay.       
Supplier BD Biosciences, 2350 Qume Drive, San 
Jose, CA USA 95131 
Fluorescent conjugated antibody Product number  
BD Pharmingen™ CD3 APC  555335 
BD Pharmingen™ CD4 PERCP 345770 
BD Pharmingen™ CD27 FITC 555440 
BD Pharmingen™ CD62L PE  341012 
BD Pharmingen™ CD195 PE (CCR5) 555993 
BD Pharmingen™ CCR7 PE 552176 
BD Pharmingen™ CD5RA PE  555489 
BD Pharmingen™ CD69 FITC 555530 
BD Pharmingen™ CD45RO PE 555492 
BD Pharmingen™ CD8 PerCP 345774 
BD Pharmingen™ CD25 FITC 555431 
BD Pharmingen™ CD19 PerCP 345778 
BD Pharmingen™ CD56 PE 555516 
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BD Pharmingen™ TNF APC 340534 
BD Pharmingen™ IL-2 FITC  340448 
BD Pharmingen™ IL-10 PE 559330 
BD Pharmingen™ IgG1 FITC 349041 
BD Pharmingen™ IgG1 PE  349043 
BD Pharmingen™ IgG2a PE 340459 
BD Pharmingen™ IgG1 APC 550874 
BD Pharmingen™ IgG2a PerCP 349054 
 
2.4.  The ELISpot Assay 
 
The ELISpot assay was used to measure IFN-γ production in response to re-stimulation 
by a range of MTB antigens, during the study period (81).  The assay was always 
performed using batched cryopreserved study PBMC (124). 
 
2.4.1.  Preparation of the PBMC 
The PMBC were thawed and rested overnight as follows (116).  The cryotubes were 
removed from the vapour phase in the liquid nitrogen storage tank and immediately 
transferred to dry ice within a sealed styrofoam container inside a fume cabinet.  
Immediately after transfer the screw caps were loosened to allow any vapour to escape 
and thereafter were transferred to a 37˚C incubator to defrost.  
 
When just a small bit of ice remained in the vial, it was transferred to the bio-safety 
cabinet; the outside surface wiped with 70% ethanol and the contents of the vial added, 
drop wise, to 10 mls of warm RPMI/10% HI FCS.  The cells were pelleted by 
centrifugation at 600g for 10 minutes.  The supernatant fluid was decanted and the pellet 
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A cell count was performed using 0.4% Trypan blue, to establish viability, as described 
in Section 2.2.1.  The cells were re-pelleted and re-suspended to a final concentration of 
2x106 cells per 1 ml of RPMI/10% HI FCS.  The cells were incubated and rested 
overnight in a 37˚C incubator with 5% CO2.  The following morning the cells were re-
pelleted, the cell count repeated and the PBMC were re-suspended in RPMI/10% HI FCS 
to the concentration of cells per ml required.  The rested PBMC were re-suspended at a 
minimum concentration of 2x106 cells/ml and a maximum concentration of 3x106 
cells/ml, depending on availability. 
  
2.4.2.  Inoculation and development of the ELISpot assay 
The ELIspot assay was performed on a sterile, high protein binding, multi-screen, 96 well 
plate.  The membranes inside the wells were pre-wetted with 50µl PBS. The PBS was 
removed and an anti-human IFN-γ monoclonal coating antibody, 1-D1K, was added to 
each well at a final concentration of 15µg/ml in 100µl.  The plate was covered and 
incubated overnight at 4˚C to allow for binding of the coating antibody to the membrane. 
Following overnight incubation the coating antibody was carefully removed using a 
multi-channel pipette and the wells were washed 5 times with 100µl RPMI, per wash. 
The wells were blocked using RPMI/10% HI FCS, 100µl per well, for 2 hours at 37˚C 
with 5% CO2.  After removing the blocking medium, the PMBC (thawed the day before 
and rested overnight) were added at a minimum of 200 000 cells/100µl per well, and a 
maximum of 300 000 cells/100µl per well.  
 
The following endotoxin free, MTB antigens were used as stimulants at predetermined 
concentrations (one stimulant per well): 
1. ESAT-6 (Rv3875), a secreted species-specific antigen, at a final concentration of 
5µg/ml. 
2. CFP-10 (Rv3874), a secreted species-specific antigen, at a final concentration of 
2.5µg/ml. 
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4. ACR2 (Rv0251c), a cytoplasmic heat shock protein, at a final concentration of 
20µg/ml. 
5. TB10.3 (Rv3019c), a homologue of the ESAT-6 family, at a final concentration 
of 2.5µg/ml 
6. PPD, a MTB culture filtrate extract, at a final concentration of 5µg/ml. 
 
 After addition of the stimulants the plates were covered and incubated at 37˚C with 5% 
CO2 for 18-24 hours.  Following incubation, the supernatant was gently removed, using a 
multi-channel pipette, after which the wells were washed 5 times each, with 100µl of PBS 
per well.  A biotinylated, anti-IFN-γ detection antibody, 7-B6-1-Biotin, was added to each 
well at 50µl per well at a concentration of 1µg/ml in PBS.  The plates were incubated at 
room temperature for 2 hours.  After incubation the plates were washed 5 times with PBS 
and a Streptavidin-alkaline phosphatase (ALP) antibody was added at 50µl per well at a 
dilution of 1:1000 in PBS.  The plates were incubated at room temperature for 1 hour and 
then washed 5 times with 100µl of PBS per well.  An ALP substrate solution was added to 
each well at 50µl per well.  The plate was left to develop for 5-15 minutes, until the 
formation of spots was clearly visible.  The reaction was stopped by washing the wells 
with tap water after which the plates were air-dried by the airflow in the bio-safety 
cabinets. 
All the ELISpot plates were read on an Immunospot Series 3B Analyzer (Cellular 
Technology, Cleveland, OH).   
2.4.3.   Positive and negative controls used in the ELISpot assay 
The ability of the study PBMC to release cytokine was validated by the inclusion of a 
positive control well at each time point.  The PBMC used in the positive control were 
stimulated using the mitogen, Phytohaemagglutin (PHA) at a concentration of 5µg/ml.  A 
negative, unstimulated control well, used to verify non-specific background staining, was 
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2.4.4.  Verification of the ELISpot CD4+ T cell IFN-γ response 
In order to validate that the IFN-γ measured in the ELISpot assay were due to CD4+ T cell 
re-stimulation, a control experiment was performed on PBMC (n=4) from which the CD4+ 
T cells were depleted using Dynabeads CD4®.  Dynabeads CD4® contains anti-CD4 
coated, super paramagnetic polystyrene beads in suspension (125)(126).   
 
2.4.4.1.  Preparation of PBMC 
The PBMC were thawed, rested, and re-suspended as described in Section 2.4.1, to a 
concentration of 2.5x106 cells/ml.  A 1ml aliquot of the re-suspended cells was aspirated 
and transferred into a sterile closed tube for use as an un-depleted control.  The remaining 
PBMC were re-pelleted by centrifugation at 600g for 10 minutes, and re-suspended in 
wash buffer (PBS without (w/o) Calcium (Ca) and Magnesium (Mg) and 0.1% Bovine 
serum albumin (BSA)), at a concentration of 107 cells/ml, in a volume determined by the 
post-resting cell count.  The re- suspended PBMC was placed on ice till further processing. 
 
2.4.4.2.  Preparation of the Dynabeads CD4®  
Dynabeads CD4® were supplied at a concentration of 4x108 beads per ml in buffer 
consisting of PBS pH 7.4, 0.1% BSA and 0.02% NaN3.  The vial of Dynabeads CD4® was 
gently mixed to ensure even distribution of the beads in suspension.  The concentration of 
Dynabeads CD4® used was 55µl per 107 cells/ml.  A 55µl aliquot of the beads was 
transferred to a 2ml screw-capped, sterile tube.  The NaN3 was removed by washing the 
beads in 1ml of wash buffer (PBS w/o Ca, Mg/ 0.1% BSA).  
 
 After addition of the wash buffer to the tube, the tube was gently mixed and then placed in 
a Dynal Magnetic Particle Concentrator ®  (Dynal MPC®), which draws the beads to the 
wall of the tube via a magnetic field.  After 1 minute, the wash buffer was gently removed 
from the tube in the Dynal MPC™, using a pipette, and discarded.   
The bead containing tube was removed from the Dynal MPC™ and the beads were re-
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2.4.4.3.  Depletion of CD4+ T cells 
The 55µl of washed beads was added to the PBMC suspension, which had been kept on 
ice, gently mixed and further incubated on ice to prevent phagocytosis of the beads.  The 
mixture was incubated for a total of 30 minutes on ice, during which, the tube was gently 
mixed every 5-10 minutes to prevent the beads from settling on the bottom of the tube. 
After the incubation, the tube was placed in the Dynal MPC™ for 1 minute, the 
supernatant was gently removed, using a pipette, and transferred to a sterile tube.  
The tube containing the bead-bound CD4+ T cells was removed from the Dynal MPC™ 
and discarded.   
 
The CD4+ T cell depleted fraction was re-pelleted at 600g for 10 minutes and re-suspended 
in at a concentration of 2.5x106 cells per ml in a volume determined by the post-resting cell 
count.  Using the ELISpot assay as described in Sections 2.4.2 and 2.4.3, the CD4+ T cell 
depleted cells and the aliquot of undepleted PBMC were set up, in order to validate the 
effect of CD4+ T cell depletion on the secretion of IFN-γ.  Depletion efficiency was 
verified by the flow cytometry assay using, a combination of anti-CD3, anti-CD4 and anti-
CD8, as described in Section 2.3.1.1. 
 
2.4.5.  Interpretation of the ELISpot assay results  
Results were expressed as spot forming cells (SFC) per million PBMC. 
A negative result was defined as <5 spots per well. 
A positive result was defined as >5 spots per well and twice the background value. 
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2.4.6.  Materials and reagents 
Table 8.  Materials and reagents used in the Elispot assay. 
PRODUCT SUPPLIER AND PRODUCT NUMBER 
(#) 
RPMI 1640 See Table 2 
Fetal calf serum, endotoxin free See Table 2 
Trypan blue 0.4% See Table 2 
Fast-Read 102, disposable counting 
chambers 
See Table 2 
Multiscreen® 96-Well Plates Millipore Ireland BV, Tullagreen, 
Carrantuohill, Country Cork, Ireland 
#MAIP N45 10 
ELSIPOT ASSAY FOR HUMAN 
INTERFERON-γ: 
Coating mAb (1-D1K) 





Recombinant ESAT-6 (Rv3875) Proteix, Prague, Czech Republic 
Recombinant CFP-10 (Rv3874) Proteix, Prague, Czech Republic 
Recombinant ACR1 (Rv2031c) Proteix, Prague, Czech Republic 
Recombinant ACR2 (Rv0251c) Proteix, Prague, Czech Republic 
Recombinant TB10.3 (Rv3019c) Proteix, Prague, Czech Republic 
Tuberculin Purified Protein Derivative 
(PPD) 
See Table 6 
BCCP/NBT (PLUS), Alkaline phosphatase 
substrate 
Moss Inc P.O. Box 189, Pasadena, 
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Phosphate Buffered Saline See Table 2 
Bovine Serum Albumin Sigma-Aldrich, South Africa 
#A9418 
2.0ml Graduated Free Standing Screw Cap 
Micro tube, Sterile with O-ring 
Quality Scientific Plastics (QSP), 
Whitehead Scientific (Pty) Ltd., 
Brackenfell 7561, South Africa 
#520-GRDS 
Dynabeads CD4®  Invitrogen Dynal AS, Oslo, Norway 
#111.45D 
Dynal MPC®   
 
Invitrogen Dynal AS, Oslo, Norway 
#120-01D 
BD Pharmingen™ CD3 FITC  BD Biosciences, 2350 Qume Drive, San 
Jose, CA USA 95131 
#345763 
BD Pharmingen™ CD4 APC BD Biosciences, 2350 Qume Drive, San 
Jose, CA USA 95131 
#345771 
BD Pharmingen™ CD8 PerCP See Table 7 
 
2.5.  CD4 counts and viral loads 
 
The blood samples drawn for the CD4 count and viral load, per time point, were submitted 
to the accredited National Health Laboratory at Groote Schuur Hospital for analysis.  The 
results were obtained using internationally approved and validated standard diagnostic 
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2.6.  Statistical Analysis 
 
All statistical analysis of data was performed using Graph Pad Prism, Version 5.0a, for 
Mac OS X.  The data were tested for normality using the D’Agostino and Pearson 
normality test.  Data that were normally distributed were analysed using analysis of 
variance (one way ANOVA) and Dunnett’s post-test for multiple comparisons, or the 
paired t-test.  These results are shown as means ± standard deviation.   
 
Data that were not normally distributed were analysed using the Kruskal Wallis test and 
Dunn’s post-test correction, or Wilcoxon matched pairs test, for paired observations and 
the Mann Whitney U test for unpaired observations.  These results are shown as medians 
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Chapter 3.  Results  
 
3.1.  Study participants, CD4 counts, and viral loads 
 
A total of 28 participants were recruited and enrolled to the study. 
Nine participants were excluded from the final analysis due to the following reasons: 
1. Two developed active tuberculosis during the study 
2. Three relocated to a different treatment centre 
3. One defaulted cART 
4. One withdrew from the study  
5. One died in a car accident 
6. One died prior to starting cART 
The remaining 19 participants, who completed the study, were included in the final 
analysis.  They participated as follows:   
1. Thirteen attended all follow up visits 
2. Five missed one follow up visit 
3. One missed two follow up visits  
 
None of the 19 participants developed active TB or opportunistic infections caused by 
non-tuberculous Mycobacteria during the study period.  Nine participants had 
documented evidence of previous TB.  The baseline characteristics and follow up results 
discussed are presented in Table 9.   
 
The median age of the 19 participants was 35 years (IQR 32-39).  Of the 19, 7 were 
males and 12 females.  9/19 participants had documented evidence of previous TB 
disease in the years preceding cART.  While this adds a degree of heterogenecity to the 
study cohort, there was no significant difference between the median age, 34 and 36 years 
respectively, of the group who had previous TB (n=9, 8 females) and the group who did 
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The median baseline viral load was 103,419 copies/ml (IQR 11,000-250,000).  The viral 
load declined to low or undetectable levels by the 24th week of cART.  The median 
baseline viral load for the group who had no previous TB was 67,710 copies/ml.  The 
median baseline viral load for the group who had previous TB was 179,759 copies/ml.  
Although the latter is higher, the difference is not statistically significant (p=0.6). 
 
CD4 counts were not available for all the participants at all the time points (individual 
results are presented in tables in Appendix 3).  Thus comparisons could not be made 
between all the time points.  A comparison made between week 0 (n=19), and week 48 
(n=18), revealed a highly significant (p<0.0001) increase in absolute CD4 count over the 
48 weeks of the study period.  The median count increased from a baseline of 93 (IQR 
40-131) at week 0, to 313 (IQR 236-434) at week 48.  A comparison of the median CD4 
counts at baseline, and the median CD4 counts at 24 weeks, between the group who had 
previous TB and the group who had no previous TB, revealed no significant difference.   
 
            p<0.001 
 
    
Figure 7.  Changes observed in the median expansion of the absolute CD4 count 
during cART.  A significant increase (one way ANOVA, p<0.001) occurred between 
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Table 9.  Baseline characteristics, CD4 counts and Viral loads. 
 
Viral Load (copies/ml) 
 








Baseline 24 week Baseline 24 week 48 week 
1 41 YES 1,030 LDL * 141 183 209 
2 35 NO 32,000 230 161 302 413 
3 46 YES 21,000 LDL 63 353 302 
4 25 YES 180,000 LDL 23 295 472 
5 44 YES NA§ 280 ** 147 567 439 
6 37 NO 500,000 <50 22 126 270 
7 32 YES 250,000 LDL 309 356 NA 
8 38 YES 102,888 <50 93 179 293 
10 35 NO 2,400 LDL 108 104 232 
11 30 YES 500,000 <50 131 535 552 
13 38 NO 11,000 <50 86 295 357 
14 40 NO 103,419 52 103 336 323 
17 32 NO NA LDL 61 117 162 
20 39 NO 380,000 <50 118 248 323 
21 38 NO 140,000 20,000 ** 99 194 429 
22 30 NO 2,400 LDL 90 140 89 
24 26 NO NA LDL 11 209 253 
25 32 YES 179,759 87 40 115 240 
28 34 YES NA LDL 3 312 
531 
MEDIAN  35    103,419  93  313 
* Lower than detectable level 
§ not available 
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3.2.  T cell phenotype and function  
T cell phenotype and function were analysed using the Flow Cytometry methods 
described in Sections 2.2 and 2.3 and the combinations of antibodies shown in Table 3.   
 
3.2.1.  Instrument settings and controls 
A representative FACSComp TM software generated report and a representative report of 
final settings used, following PBMC optimization, are presented in Appendix 1 and 2, 
respectively. 
 
3.2.2.  Antibody titrations 
Antibody titrations were performed on surface phenotype and cytokine molecules.  Figure 
8 presents a representative result.  The volumes of antibody providing optimal fluorescence 




Figure 8.  Anti-CD4 titration.  Representative graph, (n=1), showing median 
fluorescent intensity on the Y-axis and volume of antibody used on the X-axis.  The  % of 
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3.2.3.   PBMC controls 
The unstained, unstimulated negative control, performed at all time points, showed nil 
fluorescence throughout the study (<0.3% = nil), and thus was not subtracted from the 
stained study PBMC results.  The routine isotype controls also showed nil fluorescence 
(not shown). 
 
The SEB stimulated positive control, Figure 9, performed at all time points, showed a 
median IFN-γ response of 5.7% throughout the study.  
 
A       B 
                   
Figure 9.  Representative responses for the SEB stimulated controls.  Scatter dot 
plots, (n=1), showing representative responses for the SEB stimulated controls.  Plot A 
shows IFN-γ staining and Plot B shows TNF staining. 
 
In addition to the schedule of PBMC controls presented in Table 5, the effect of 
incubation time on non-specific staining, auto-flourescence and up-regulation of surface 
molecules was assessed (127).  PPD stimulated and un-stimulated PBMC were tested at 
0,2,4,6, and 18 hours for each control.  The isotype and unstained negative controls 
showed nil fluorescence throughout the experiment (<0.3% = nil), Table 10 presents 
representative results for the negative control.  The 4-colour control showed that 
overnight incubation did not result in up-regulation of surface molecules; Figure 10 
presents representative results for the 4-colour and isotype controls.   
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Table 10.  The effect of incubation time on the negative unstained controls.   
 
Negative unstained controls recorded as percentage of PBMC negative 
 PPD stimulated  Unstimulated  
Hours incubated 0 2  4 6 18 0 2 4 6 18 
FL1-FL2- 100 100 100 100 100 100 100 100 100 100 
FL1-FL3- 100 100 100 100 100 100 100 100 100 100 
FL1-FL4- 100 100 100 100 100 100 100 100 100 100 
FL2-FL3- 100 100 100 100 100 100 100 100 100 100 
FL2-FL4- 100 100 100 100 100 100 100 100 100 100 
FL3-FL4- 100 100 100 100 100 100 100 100 100 100 
 
 
Table 10.  Representive results, (n=1), for the PPD stimulated and un-stimulated 






































Figure 10.  The effect of incubation time on the stained positive controls. Graphs A, 
B and C show representative results, (n=1), for the PPD stimulated and un-stimulated 
responses observed at 0,2,4,6, and 18 hours for the surface molecules CD4, CD27, and 
CD45RA, respectively as well as the PE, FITC and PERCP isotype controls.    
In the same manner, Graph D shows the responses observed for the cytokine, IFN-γ and 
compares the PMBC, APC isotype, and SEB controls.  The unstimulated, stained isotype 
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3.2.4.  CD4+ T cells 
 
CD4+ T cells were identified using the SSC and FL3-CD4 PerCP parameters, and selected 
by gating.  The percentage of CD4+T cells increased significantly from a baseline of 
7.3±4.8%, to 17.4±7.1% (p<0.0001, Figure 11) by 48 weeks of cART.  This parallels the 
increase observed in the absolute CD4 count. 
 
                  p < 0.0001 
 
Figure 11.  The mean expansion of the CD4+ T cells. Scatter dot plot showing the mean 
expansion of CD4+ T cells (n=19), as determined by flow cytometry during the 48-week 
study period, which increased significantly over time (p<0.0001). 
 
 
The CD4+ population was further analysed on the basis of surface expression, or lack of 
surface expression, of the molecules presented in Table 1, Section 1.3.3.  Scatter dot plots, 
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A    B    C 
    
D    E    F 
         
 
 
Figure 12.  The gating strategy used for the CD4+ T cells.  Representative scatter dot 
plots showing the gating strategy used for CD4+ T cells (n=1).  CD4+ T cells were 
identified and gated using the SSC and FL3-PERCP parameters as shown in Plot A.  The 
CD4+ population was further analysed as shown in Plots B, C, D, E, and F.  Plot B shows 
the CD4+ INFγ+ T cell gating using the FL3-PERCP and the FL4-APC parameters.  A 
similar strategy was applied to the identification of the CD4+IL2+, CD4+IL10+, and 
CD4+TNF+ populations (not shown).  Plots C, D, E and F shows the gating strategy using 
the FL1 and FL2 parameters, to determine the expression of CD27, CCR5, CCR7, 
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3.2.4.1.  Naïve CD4+T cells  
Naïve cells were identified by the co-expression of the CD27 and CD45RA molecules.  At 
the time of starting cART, the mean proportion of the CD4+CD27+CD45RA+ population 
was 16.1±12.8%.  A significant change occurred at week 36, when it increased to 
25.2±15.3% (p= 0.0017, Figure 13).  This increase was sustained at week 48 (27±15.4%, 
p=0.008). 
    p=0.0008 
 
 
Figure 13.  Changes observed in the mean expansion of theCD4+CD27+CD45RA+ 
population during cART.  Before and after plot showing the mean expansion of the 
CD4+CD27+CD45RA+ population, which showed a significant increase at week 36, 
sustained at week 48, (n=19).     
  
3.2.4.2.  Central memory CD4+ T cells 
Central memory cells were identified by the expression of the CD27 molecule and the lack 
of expression of either the CD45RA or the CCR5 molecule.  The mean percentage of the 
CD4+CD27+CD45RA- population at week 0 was 34.2±17.8.  It increased significantly to 
47.8±14.6% (p=0.0001, Figure 14A) at week 12, and remained significantly higher until 
week 48 (46.3±12.1%, p=0.002).  This increase was paralleled by the change observed in 
the CD4+CD27+CCR5- population, which increased from a mean of 52.3±29.5% at week 0, 
to a mean of 58±22.2% at week 12 and continued to increase until week 48 (67.1±20.1%, 
p=0.02, Figure 14B). 







































                         p = 0.03 
 




                           p = 0.02 
 
 
Figure 14.  Changes observed in the mean expansion of theCD4+CD27+CD45RA-
population during cART.  Before and after plot A, shows the mean expansion of the 
CD4+CD27+CD45RA-population, (n=19), which increased significantly by 12 weeks 
(p=0.001) and remained significantly higher until week 48 (one way ANOVA, p=0.03).  
Before and after plot B, shows the mean expansion of the CD4+CD27+CCR5- population, 
(n=19), which also proportionally increased by 12 weeks (p=0.01) and remained 
significantly higher until week 48 (p=0.02).   
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3.2.4.3.  Effector CD4+ T cells 
The proportion of CD4+ T cells expressing CCR5 (effector memory and terminally 
differentiated effector T cells) varied widely between the study participants as presented 
in Figure 15A.  The median at week 0 was 5.8% (IQR 3-12).  It steadily decreased 
during the study period and significantly by week 48 (2.7%, IQR 2.1-4.8, p=0.02 
compared to week 0).  Terminally differentiated effector T cells were also analysed by 
their lack of expression of CD27 and CCR7.  The mean percentage of the CD4+CD27-
CCR7- T cell population at week 0 was 50±29.1%.  This decreased significantly to 
38.2±20.4% (p=0.02) at week 12 and continued to decrease until week 48 (32±20.2%, 
p=0.02 compared to week 0) and supports the change observed in the CD4+CCR5+ T cell 
population.   
 
A 
         p=0.02  
       
Figure 15A.  Changes observed in the median decrease in the proportion of the 
CD4+CCR5+ population during cART.  Before and after plot A shows the median 
decrease in the proportion of the CD4+CCR5+ population, (n=19).  A significant change 
occurred at week 48 when it decreased to 2.7% (IQR 2.1-4.8, p=0.02) compared to 5.8% 
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B                         p=0.02 
 
 
Figure 15B.  Changes observed in the mean decrease of the percentage of the 
CD4+CD27CCR7-, terminally differentiated effector T cells during cART.  Before 
and after plot B shows the mean decrease in the percentage of the CD4+CD27-CCR7-, 
terminally differentiated effector T cells, (n=19).  A significant decrease occurred at week 
12 (p=0.02), which was sustained until week 48 (p=0.02).  
 
 
3.2.4.3.  Activated CD4+ T cells 
The PPD stimulated PBMC were also analysed for the expression of the activation 
markers CD69 and CD25, as presented in Figure 16 (128).   
The median proportion of the CD4+CD69+ T cells was 1.6% (IQR 1.4-3.8) at week 0 and 
1.5% (IQR 1.0-2.1) at week 48.  The majority of the CD4+CD69+ population also 
expressed CD45RO, a marker of memory cells.  The median proportion of the 
CD4+CD69+CD45RO+ population was 1.67% (IQR 1.2-3.3) at week 0 and 1.3% (IQR 
0.8-1.6) at week 48, Figure 17.  The expression of CD25 was also low.  The median 
proportion of CD4+CD25+ T cells was 2.3% (IQR 0.85-6.55) at week 0 and 1.4% (IQR 
0.91-3.67) at week 48, Figure 18.  The expression of these activation markers did not 
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         A                                                                    B 
                                   
Figure 16.  The identification of the CD4+CD45RO+CD69+ and the  
CD4+CD25+ T cells.  Scatter dot plot A shows the identification of the 
CD4+CD45RO+CD69+ T cells using the FL2-CD45RO PE and FL1-CD69 FITC 
parameters, (n=1).  Plot B shows the identification of the CD4+CD25+ T cells using the 




   A                                                                         B  
     
Figure 17.  The median proportions of the CD4+CD69+ T cells, and the CD4+CD69+ 
T cells expressing CD45RO.  Scatter dot plot A shows the median proportions of the 
CD4+CD69+ T cells, (n=19), during the study period, of which the majority also 
expressed a memory phenotype as determined by the expression of CD45RO, shown in 
























































































































Figure 18.  The median proportions of the CD4+CD25+ T cells.  Scatter dot 
plot showing the median proportions of CD4+CD25+ T cells during the study 
period, (n=19).  No significant change occurred.  
 
3.2.4.4.  Cytokine producing CD4+ T cells 
The median proportion of PPD specific CD4+ IFN-γ producing cells was 0.92% (IQR 
0.28-1.38) at week 0 and decreased significantly to 0.35% (IQR 0.17-0.52) at week 48 of 
the study period (p=0.021) as presented in Figure 19A.  The majority of the CD4+ IFN-γ 
producing cells were of a memory phenotype as >80% expressed CD45RO throughout 
the study period, as presented in Figure 20.  Similarly, analysis of the CD4+ IL-2+ T cells 
revealed a significant decrease from a median of 0.43% (IQR 0.27-1.3) at week 0 to a 
median of 0.2% (IQR 0.14-0.36) at week 48, Figure 19B.  The expression of IL-10 in the 
CD4+ population was variable, showing a median of 0.36% (IQR 0.22-0.8) at week 0, 
which increased to 0.63% (IQR 0.21-3.12) at week 2 (p=0.06), and decreased to 0.31% 
(IQR 0.14-0.53) at week 48 resulting in no overall change during the study period as 
presented in Figure 19C.  
 
The detection of the proportion of CD4+ CD25+ T cells producing IL-10 was extremely 
low, with a median of 0.09% (IQR 0.03-0.29) at week 0 and 0.02% (IQR 0.01-0.07) at 
week 48 (not shown).  Analysis of TNF expression in the CD4+ T cell population showed 
no significant change between week 0 (median 0.34%, IQR 0.16-1.1) and week 48 
(median 0.31% IQR 0.15-0.63), Figure 19D. 
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A   p=0.021   B       p=0.006 
 
C                              D            
Figure 19.  The median proportions of the cytokine producing CD4+ T cells. Scatter dot plots 
showing the median proportions of cytokine producing CD4+ T cells, (n=19).  Plot A shows the 
significant decrease of the CD4+ IFN-γ producing T cells from 0.92% (IQR 0.28-1.38) at week 0 
0.35% (IQR 0.17-0.52) at week 48.  Similarly, Plot B shows the significant decrease in the CD4+ 
IL-2+ T cells from a median of 0.43% (IQR 0.27-1.3) at week 0 to a median of 0.2% (IQR 0.14-
0.36) at week 48.  Plots C and D shows the CD4+IL-10+and the CD4+TNF+T cells, respectively, 
which showed no significant change during the study period. 
 
 
Figure 20.  The identification of the CD4+IFN-γ+CD45RO+ T cells.  Scatter dot plot 
showing the identification of the CD4+IFN-γ+CD45RO+ T cells using the FL4-IFN-γ APC 
and the FL3-CD45RO PERCP parameters, (n=1).  







































































































The expression of the CD4+ IFN-γ+, CD4+ IL-2+ and CD4+ IL-10+ T cells at 48 weeks of 
cART were compared to the expression of the same T cell populations in twelve HIV 
uninfected, MTB sensitized adults (Section 2.1).  The cytokine secreting CD4+ T cells 
detected in the HIV infected adults were significantly lower than those detected in the 
HIV uninfected controls from the same population.  The HIV uninfected controls showed 
a median proportion of 0.73% (IQR 0.5-0.85) for CD4+ IFN-γ+ T cells, 0.6% (IQR 0.43-1) 
for CD4+ IL-2+ T cells and versus 0.84% (IQR 0.6-2.4) respectively for CD4+ IL-10++ T 
cells, as presented in Figure 21. 
 
       p=0.004          p=0.0001         p=0.001 
 
 
Figure 21.  Comparison of cytokine production in HIV infected adults, (n=19), on 
cART for 48 weeks to HIV uninfected adults, (n=12), from the same community.  
The median proportion of CD4+IFN-γ+T cells was 0.35% (IQR 0.17-0.52) versus 0.73% 
(IQR 0.5-0.85) respectively.  The medians of the CD4+ IL2+ T cells were 0.2% (IQR 0.15-
0.36) versus 0.6% (IQR 0.43-1) respectively and those of the CD4+ IL10+ T cells were 
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3.2.5.  CD8 T cells 
CD8+ T cells were identified using the SSC and FL3 (CD8 PerCP) parameters, and selected 
by gating as presented in Figure 22.  The median proportion of CD8+ T cells at week 0 was 
55% (IQR 39-61).  This did not change significantly over the study period, with the 
median proportion at week 48 being 53% (IQR 43-64, p=0.94), Figure 23. 
 
 
Figure 22.  The gating strategy used for CD8+ Tcells.  Scatter dot plot showing the 
gating strategy for CD8+ Tcells, (n=1), which were isolated using the SSC and FL3-
PERCP parameters.  
 
 
Figure 23.  The gating strategy used for CD8+ Tcells.  Scatter dot plot showing the 
median proportions of the CD8+ T cell population over the study period, (n=19).  No 
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3.2.6.  B lymphocytes (B cells) 
 
B cells were identified using a combination of anti-CD3 and anti-CD19.  The lymphocyte 
population was selected by gating, using the FSC and SSC parameters as presented in 
Figure 24.  The lymphocyte population was further analysed to identify the CD3-CD19+ B 
cell population using the FL4-APC and the FL3-PerCP parameters.  The median 
proportion of the B cell population declined significantly from a median of 2.27% (IQR 
1.3-5.7) at week 0 to 1.26% (IQR 0.6-2.3, p=0.012) at week 48, Figure 25. 
A      B 
  
Figure 24.  The gating strategy used for B cells.  Scatter dot plots showing the gating 
strategy for B cells, (n=1).  The lymphocyte population was identified using the SSC and 




  p=0.012 
 
Figure 25.  B cells detected during the study period.  Scatter dot plot plot 
showing B cell detection during the study period, (n=19).  The median proportion 
of B cells declined significantly from 2.27% (IQR 1.3-5.7) at week 0 to 1.26% 
(IQR 0.6-2.3, p=0.012) at week 48.  
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3.2.7.  NK and NKT cells 
NK and NKT cells were identified using a combination of anti-CD3 and anti-CD56.  The 
lymphocyte population was gated as shown in Figure 26, and further analysed to identify 
NK cells as CD3-CD56+ and NKT cells as CD3+ CD56+, using the FL4-APC and the FL2-
PE parameters as presented in Figure 27 A and B.  The median proportion of the NK cells 
at week 0 was 4.3% (IQR 2.8-15.2), which nearly doubled over the study period to 8.3% 
(IQR 3.6-12.10).  The median proportion of the NKT population did not change 
significantly over the study period either, changing from 3.6% (IQR 2.5-5.2) at week 0 to 
4.6% (IQR 3-5.7) at week 48, a difference that was not statistically significant, Figure 27 
A and B. 
  
                                              
Figure 26.  The detection of NK and NKT populations.  Scatter dot plot showing 
detection of NK and NKT populations using the FL4-CD3 APC and FL2-CD56 PE 
parameters, (n=1).  NK cells were identified as CD3-CD56+ and NKT cells as CD3+ 
CD56+. 
 
                   A                                                                     B 
 
 
Figure 27.  The median proportions of the NKT and NK cells.  Scatter dot plots A and 
B shows the median proportions of the NKT (n=18), and NK cells (n=19), respectively, 
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3.3.   The CD4+ T cell IFN-γ  response to re-stimulation by MTB antigens  
 
IFN-γ secretion in response to the antigens listed in Section 2.4.4 was measured using the 
ELISpot assay described in Section 2.4.  The ELISpot results were interpreted as stated in 
Section 2.4.5. 
 
3.3.1.  PBMC viability and function 
The isolation of viable and functional PBMC may be affected by various factors in the 
isolation process, including cryopreservation (116).  Following the thawing and resting 
process, the viability of the PBMC was assessed using Trypan blue as described in Section 
2.2.1.  The viability of all the PBMC used in the ELISpot assay was >80%.   
The functional capability of the PBMC used in the ELISpot assay was also assessed using 
the flow cytometry, by comparison of its IFN-γ secretion in response to SEB stimulation, 
to that of freshly isolated PBMC (116).  The PBMC were re-stimulated and stained as 
described in Section 2.3.2.  The median proportion of the freshly isolated PBMC, secreting 
IFN-γ, was 13.2% (n=6) compared to a median proportion of 12.3% for the cryopreserved 
IFN-γ secreting PBMC  of the same samples. 
  
3.3.2.  Controls 
The PHA stimulated control well had a SFC of  >5 spots per well, and twice the SFC of the 
negative control well, for each time point tested.  The SFC of the unstimulated negative 
control wells, if any, were subtracted from the MTB antigen restimulated SFC.  Figure 28 
is representative of the study PBMC ELISpot results obtained.   
 
                            ESAT-6            ACR1             TB10.3          PHA   
 
                                      CFP-10            ACR2              PPD               Un-stimulated 
 
Figure 28.  Representative PBMC ELISpot results.  The restimulating antigen used is                 
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3.3.3.  Verification of the ELISpot CD4+ T cell IFN-γ response 
Verification of the CD4+ T cell IFN-γ secretion in the ELISpot assay was performed as 
described in Section 2.4.4.  Four cryopreserved samples (two from week 36 and two from 
48 week) were used in the CD4+ depletion experiments.  The efficacy of the CD4+ 
magnetic bead depletion, was assessed using the surface phenotype staining method 
described in Chapter 2, and was found to be 90 ± 5% efficient.   
 
The depletion of the CD4+ T cells resulted in a mean decrease in the secretion of INF-γ, in 
response to MTB specific antigen re-stimulation, as follows: 
1. 82±11% for ESAT-6  
2. 90±10% for CFP-10  
3. 86±12% for ACR1  
4. 75±7% for ACR2 
5. 86±4% for TB10.3 
The bar graph in Figure 29, presents the effect of CD4+ T cell depletion on the IFN-γ 
secreting response detected in the ELISpot assay. 
 
Figure 29.  The mean decrease in the IFN-γ  SFC, following CD4+ T cell depletion.  
Bar graph showing the mean decrease in the IFN-γ SFC, following CD4+ T cell depletion 
in the ELISpot assay, (n=4). 
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3.3.4.  Detection of LTBI  
LTBI was established on the basis of an IFN-γ response to the RD1 encoded antigens 
ESAT-6 and CFP-10, in the ELISpot assay (88,89).  Participants, who were unable to be 
tested at week 0, were tested at either week 2 or week 4 of cART.  Two participants did 
not show a detectable IFN-γ response at week 0, but developed a detectable IFN-γ 
response by 2 weeks into cART.  Thus it was established, within the first month of starting 
cART, that all participants enrolled had LTBI.  The summed response to ESAT-6 and 
CFP-10, at the time of starting cART, showed a mean of 376 (±482) SFC /106 PBMC.  
 
3.3.5.  MTB antigen specific IFN-γ ELISpot responses  
The number of cryopreserved PBMC available determined the number of antigens tested 
in the ELISpot assay.  Preference was given to the inclusion of PPD, ESAT-6 and CFP10 
(as these are antigens currently used in the ascertainment of LTBI), as well as the PHA 
and negative control.  Thus the data for TB10.3, ACR1, and ACR2 do not reflect all the 
time points.  As stated in Section 2.6, means are shown for normally distributed data and 
medians are shown for data not normally distributed. 
 
3.3.5.1.  PPD 
The median IFN-γ SFC/106 PBMC at week 0, in response to PPD re-stimulation, was 7 
(IQR 1-50).  A   significant overall increase occurred by week 48, median SFC/106 PBMC 
60 (IQR 17-168, p=0.02), Figure 30.  The most significant increase occurred at week 12, 
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   p=0.02 
 
Figure 30.  Changes observed in the median IFN-γ  SFC/106 PBMC in response to 
PPD re-stimulation, during cART.  Before and after plot showing the significant 
increase in the median IFN-γ SFC/106 PBMC in response to PPD re-stimulation, from 7 




3.3.5.2.  ESAT-6 and CFP-10 
 
The summed IFN-γ SFC/106 PBMC, in response to ESAT-6 and CFP-10 re-stimulation, 
increased significantly from a mean of 376 (±482) SFC/106 PBMC at week 0, to 1077 
(±738) SFC/106 PBMC at week 48, p=0.04, Figure 31.   
The most significant increases, compared to week 0, occurred at weeks 36 and 48 weeks 









































        p=0.04 
 
Figure 31.  The summed mean IFN-γ  SFC/106 PBMC, in response to ESAT-6 and 
CFP-10 re-stimulation.  Scatter dot plot showing the significant increase in the summed 
mean IFN-γ SFC/106 PBMC, in response to ESAT-6 and CFP-10 re-stimulation, (n=16), 
from 376 (±482) at week 0, to 1077 (±738) at week 48, p=0.04,  (one way ANOVA). 
 
As as result of the heterogeneity introduced to the study, by the group who had 
previously been treated for TB, the summed IFN-γ response to ESAT-6 and CFP-10 
restimulation was also analysed according to previous TB status, on the available samples 
at week 48, Figure 32.  The summed response to ESAT-6 and CFP-10 was significantly 
higher, p=0.01, in the group of patients who did not previously receive TB therapy n=7, 
compared to those who did n=5.  The medians were 1793 SFC/million PBMC (IQR 
1397-2129), and 548 SFC/million PBMC (IQR 343-653), respectively at 48 weeks of 
cART. 














































Figure 32.  The summed response to ESAT-6 and CFP-10 of the group who had 
previous TB treatment and the group who did not.  Scatter dot plot showing the 
comparison of summed response to ESAT-6 and CFP-10 between the group who had 
previous TB treatment, (n=7) and the group who did not, (n=5), at 48 weeks of cART.  
The difference was significantly higher, p=0.01, in the group who did not have previous 
TB treatment.   
 
 
3.3.5.3.  ACR1 and ACR2 
The IFN-γ response to restimulation by ACR1 and ACR2, reflected an increase during 
the study period which was significant for ACR2, Figure 33A and 33B.  The median 
SFC/106 PBMC for ACR1 was 67 (IQR 22-1535) at week 0, and 864 (IQR 83-1313) at 
week 48.  However, the increase was not statistically significant.  The median SFC/106 
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   A                                                                B                     p=0.02 
 
   
Figure 33A and 33B.  The IFN-γ  response to ACR1 and ACR2.  Scatter dot plots 
showing the IFN-γ response to ACR1and ACR2.  Plot A shows the median increase in 
the response to ACR1, (n=9), over the study period.  No significant change occurred.  
Plot B shows the median increase in the response to ACR2, (n=9), which was significant 
at week 48, p=0.02.  
 
 
3.3.5.4.  TB10.3 
The median IFN-γ response to TB10.3 showed a significant increase from 40 SFC/106 
PBMC (IQR 30-975) at week 0, to 1296 SFC/106 PBMC (IQR 73-1387) p=0.04, at week 
48, Figure 34. 
                                                               p=0.04 
 
                          
Figure 34.  The median IFN-γ  response to TB10.3.  Scatter dot plot showing the 
significant increase in the median IFN-γ response to TB10.3 over the 48-week study 
period, (n=9).
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Chapter 4.  Discussion and concluding remarks 
 
 
4.1.  Discussion 
 
 
Studies on cART associated restoration of PPD specific responses and qualitative 
changes in CD4+ T cells have thus far been limited, to low incidence areas, in developed 
countries (109)(110)(111)(112,).  Similar analyses in areas of high incidence are lacking.  
It has also been documented that the immune response to MTB is influenced by host 
genetics (129).  Therefore previous studies may not reflect the changes that occur in a 
high incidence setting in South Africa.   
 
This study describes the restoration of cART associated PPD and MTB specific 
responses, in a cohort, within a community currently experiencing one of the highest 
rates of TB incidence.  During the 48-week study period, the significantly decreased viral 
load was accompanied by a statistically significant increase in the CD4 count and the 
percentage of the CD4+T cell population, changes well associated with effective cART. 
 
An in vitro response to the MTB antigens ESAT-6 and CFP-10, as measured in the 
ELISpot assay, was detected within the first 4 weeks of the study period in all of the 19 
participants who had completed the study, indicating LTBI (86)(89).  Since the 
prevalence of LTBI in this community has been documented at a rate of between 70% 
and 90%, this was not unexpected (130)(131)(132).  The summed responses to ESAT-6 
and CFP-10 progressively increased during the study period.  An increase of 65% 
occurred over the 48-week study period, which was statistically significant.  This data 
was supported by the parallel, statistically significant, increase in the PPD specific T cells 
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The summed response to ESAT-6 and CFP-10 restimulation was about 10 times higher 
than the reponse to PPD restimulation.  This difference most likely reflects the difference 
in antigenic composition of these stimulants.  PPD is a mixure of more than 200 proteins 
shared amongst MTB, M. Bovis BCG and other enviromental mycobacteria whereas 
ESAT-6 and CFP-10 each contain one purified antigen (85)(89)(90)(91).  The higher 
responses to the RD1 antigens, in this group of people, most likely also refect true 
sensitisation to MTB, and that these responses are preserved even at low CD4 counts, in a 
high incidence environment. 
 
Additionally, the absolute numbers of IFN-γ producing cells, responding to re-stimulation 
by the alpha crystallins ACR1 and ACR2, and the secreted Esx family protein, TB10.3, 
also increased.  Despite considerable variability, these increased responses were 
statistically significant for ACR2 and TB10.3.  The depletion of the CD4+ T cells in the 
ELISpot assay, revealed this population as the main source of IFN-γ secretion. 
 
The summed response to ESAT-6 and CFP-10 in the group who had not previously 
received TB therapy (n=10, median 1793 SFC/million PBMC), was significantly higher 
at 48 weeks of cART, when compared to that observed in the group of patients who had 
previously received TB therapy (n=9, median 548 SFC/million PBMC, p=0.01).  The 
number of RD-1 antigen specific T cells detected by the ELISpot assay has been 
associated with bacterial load (133).  Thus, the lower response detected in the group who 
had previously been treated for TB, may reflect a lower bacterial load consequent on 
beneficial antituberculous chemotherapy.  Lawn and colleagues have reported similar 
findings in 2007 on a study performed in a high TB incidence setting in South Africa 
(134).  
 
 A comparison between the proportions of central memory T cells and cytokine secreting 
CD4+ T cells, as determined by flow cytometry, revealed no differences at week 0 and 
week 48 of cART between the group who had received previous TB treatment and the 
group who had not.  This suggests that treatment of prior TB did not have a negative 
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as they support recommendations on the implementation of isoniazid preventive therapy 
in HIV infected adults sensitized with MTB (135).   
 
The ELISpot assay does not differentiate between specific T cell subsets.  It measures 
IFN-γ secreted within 6 hours of antigen re-stimulation and therefore reflect the activity 
of the acquired immunity that is able to provide a rapid effector memory response (136).  
 
The increase in PPD and MTB specific IFN-γ secreting CD4+ T cell numbers, as detected 
by the ELISpot assay, most likely reflects the reconstitution of MTB specific immune 
function, influenced by the progressive cART associated reconstitution of the CD4+ T 
cell pool (the percentage of CD4+ T cells measured in the flow cytometry assay, 
increased significantly from 7.3% to 17.4%).  
 
At the same time, the proportion of PPD specific IFN-γ secreting  CD4+ T cells 
(effectors) as measured by flow cytometry, showed a decline from 0.92% to 0.35% 
during the study period.  By comparison to the detection of absolute numbers in the 
ELISpot assay, the effector IFN-γ secreting response detected in the flow cytometry 
assay, is a measure of a proportional subset within an expanding pool.   
 
Coinciding with the significant decline in the effector population was a significant 
increase in the proportion of the central memory population at 12 weeks.  The central 
memory T cells population was identified as CD4+CD27+CD45RA-, as well as 
CD4+CD27+CCR5-.  Both combinations of surface phenotype molecules detected a 
significant expansion of the central memory population at 12 weeks.  The dynamics 
detected in the central memory, effector memory and terminally differentiated effector, 
CD4+ populations, most likely reflect cART associated reconstitution and restoration of 
immune function (137).  Thus it could be expected that as the  immune function 
qualitatively improves, the quantitative effort directed toward a specific antigen 
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 Figure 35, is a concept diagram reflecting the dynamics (corrected for CD4 count),  
detected within the reconstituting CD4+ T cell pool.  At week 0 the proportion of 
terminally differentiated effector CD4+ T cells are similar to that of the CD4+ TCM.   
 
This is a reflection of the rate at which the antigen specific TCM  are proliferating in order 
to generate effector T cells, as the immune response strives to maintain infection control.  
At week 48 the absolute numbers of each of the subtypes reflected have increased 
significantly.  At the same time, as mentioned above, the proportion of the terminally 
differentiated effector CD4+ T cells have decreased within the expanding pool.   
This is paralleled by a significant increase in the proportion of the central memory 
population.  Again, this most likely reflects cART associated restoration of immune 
function and a consequent reduction in the numbers needed to generate an effective 
antigen specific response. 
 
Weeks of CART 
Figure 35.  A concept diagram reflecting the cART associated dynamics observed within the 
reconstituting CD4+ T cell pool.  The proportion of naïve (CD4+CD27+CD45RA+), central 
memory (CD4+CD27+CD45RA-) and terminally differentiated effector (CD4+CD27-CCR7-) T 
cells were summed at each timepoint for each patient, normalised to 100% and multiplied by the 
CD4 count per 100 microliter, of each respective patient at that timepoint.  The diagram 
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The proportion of naïve CD4+ T cells (CD4+CD27+CD45RA+), showed a significant 
expansion by 36 weeks of cART.  The thymus is the primary supply of naïve T cells.  
Thymocytes express CXCR4, and are therefore a target for CXCR4 tropic HIV.  The 
observed expansion most likely reflects recovery of thymic function as a result of 
decreased damage due to viral infection and replication.  
 
Post bone-marrow transplant studies have revealed, that both thymic output, as well as 
peripheral expansion contributes to immune reconstitution following severe 
immunodepletion.  Similarly it has been shown that thymic output and peripheral 
expansion contributes to T cell reconstitution in cART treated people (100).  Deon et al, 
2004, measured T cell receptor excision circles to determine the dynamics of recent 
thymic emigrants in the pheriphery of HIV infected people, who had received anti-
retroviral treatment.  Their study showed restoration of thymic function following anti-
retroviral treatment (157).  These observations are supported by the findings of this study.  
 
MTB specific IFN-γ secretion, as a single measurement, may misrepresent the total 
cytokine response to PPD stimulation and may not be an optimal correlate of protection.  
Studies investigating the cytokine secreting, antigen specific phenotype of T cells 
responding to BCG vaccination in infants, and BCG vaccinated adults who had received 
a boosting recombinant MVA85A vaccine, detected the induction of antigen specific T 
cells secreting IL-2 and TNF (138)(139).  IL-10 has been associated with the regulation 
of effector T cell responses against TB and is induced by BCG vaccination in newborns 
(140).  
 
The proportion of CD4+IL-2+ T cells declined significantly during the study period, from 
0.43% to 0.2% over 48 weeks of cART.  This significant decrease in proliferation reflects 
the qualitative restoration of antigen specific immune function and therefore a lower 
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The variable changes observed in the proportion of CD4+IL-10+ cells, did not result in a 
significant overall change during 48 weeks.  No significant change in the proportion of 
CD4+TNF+ cells occurred between week 0 and week 48. 
 
The cytokine producing capacity of the HIV infected patients receiving cART for 48 
weeks, was compared to that of HIV uninfected controls recruited from the same 
community.  The comparison revealed that the reconstituted CD4+ T cells secreting IFN-
γ, IL-2 and IL-10 was significantly lower than that of the HIV uninfected controls 
(p<0.01 for all cytokines).  The impaired restoration of functional MTB specific CD4+ T 
cell responses, despite long-term antiretroviral treatment, has been documented (141).  
These results support those findings.   
 
TB incidence rates amongst people receiving cART in Cape Town remains higher than 
the rate amongst HIV uninfected people living in the same community (142).  Perhaps 
this difference in functional ability of the MTB specific CD4+ T cells, contributes to the 
difference in TB incidence rates described. 
 
The activation status of the CD4+ T cells was determined by the expression of CD69 and 
CD25 (128).  The level of CD69 and CD25 expression was low throughout the study 
period and showed an insignificant decrease at 48 weeks.  The CD4+CD69+ population 
was also assessed for expression of CD45RO.  The majority of the CD4+CD69+ 
population expressed CD45RO, indicating a memory phenotype, which supports previous 
observations made (112)(143).   
 
The proportion of CD8+ T cells did not change significantly over the 48 weeks of cART. 
A combination of the ethically approved volume of blood drawn and the limited PBMC 
available did not allow the detection of changes in activation of the CD8+ T cells.  Based 
on the results from previous studies, a decrease in CD8+ T cell activation would have 
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Helper T cells contribute to the induction of B cell antibody production (48).  HIV 
induced destruction of the helper CD4+ T cell population would therefore contribute to 
the HIV infected host’s ability to control infection by opportunistic pathogens, via 
antibody production.  The phenotypical and functional alteration of B cells by HIV 
infection has been shown (145).  Additionally, B cells have been shown to act as 
extracellular reservoirs for HIV, binding virions via CD21 and transporting them to T 
cells (146).  The proportion of B cells identified as CD3-CD19+ cells showed a significant 
decline from week 0 to week 48 of cART.  Again, this might reflect the cART associated, 
restoration of immune function and thus the improved quality of response would require 
fewer numbers.  B cell numbers might be affected by viral load, as decreasing viral load 
would require less HIV specific antibody production.  
 
The frequency and absolute numbers of CD3-CD56+ NK cells has been shown to   
decrease in HIV infection (147).  A combination of antiretroviral treatment and IL2 
therapy was documented to reconstitute the NK cell population.  Antiretroviral treatment 
alone did not show significant change in the NK cell population during a 1-year period of 
follow up (148).  Our study data indicated no significant change over 48 weeks of cART, 
in the proportion of CD3-CD56+ cells, supporting the finding above.  
 
The depletion of NKT cells in HIV infection has also been documented (149).  A 
previous study revealed that IL-2 therapy, in conjunction with anti-retroviral therapy, was 
associated with a significant increase in the reconstitution of NKT cells.  Anti-retroviral 
therapy alone revealed an insignificant trend of 17% in the increase of NKT cells (150).  
Our study revealed a weak, statistically insignificant reconstitution of the NKT cell 















Chapter 4                                                                       Discussion and concluding remarks 
 
 79 
4.2.  Concluding remarks 
 
A limitation of the study is the lack of a control group of persons not sensitized by MTB.  
Verification that the MTB specific changes detected are related to the restoration of 
immunity to MTB infection would require performing the same study procedures, 
including restimulation by non-TB specific antigens, in appropriate control groups.  Such 
control groups should include an equal number of HIV infected people with no prior 
sensitisation to MTB, as well as an equal number of HIV uninfected people with prior 
sensitisation to MTB.    
 
However, the current statistics on prior sensitisation to MTB as well as the rate of HIV-
TB co-infection in this high prevalence setting, as mentioned in the introduction, makes 
the recruitment of such control groups extremely difficult  (4)(5)(130)(131)(132).  This is 
confounded by the reality that no test is able to exclude prior sensitisation to MTB in HIV 
infected people.  Previous work in a low incidence setting detected MTB specific T cell 
reconstitution in HIV infected people (137).  Repeating the study in a low TB incidence 
setting might negate meaningful comparisons because findings in a genetically different 
population may not be comparable to the findings in Cape Town. 
 
Also, Samri et al, 2007, found that in HIV infected people with advanced disease, T cell 
responses to TB and Cytomegalovirus, but not HIV specific proteins, were restored 
(151).  It therefore seems unlikely that our studies findings are due to non-specific HIV 
antigen associated reconstitution.   
 
The study aimed to determine the reconstitution of different T cell types in a TB endemic 
area, where infection pressure, and thus antigen pressure, is high.  Therefore the PBMC 
used in the flow cytometry assay were PPD re-stimulated in an 18-hour incubation 
period, in an attempt to enhance MTB specific responses, as it is difficult to detect 
antigen specific responses in advanced HIV disease.  This might have resulted in an in 
vitro up regulation of surface marker expression as well as activation induced apoptosis 
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However a control experiment measuring surface marker expression at various time 
points, in PPD stimulated as well as unstimulated PBMC, revealed no change in surface 
marker expression in response to the 18 hour PPD re-stimulation. 
 
The evaluation of immunity to MTB is often measured via the rapid effector, IFN-γ 
secreting response.  However this measure has shown poor correlation with protection to 
MTB in previous studies (154).  Supporting this, a recent study in mice, on vaccine 
induced protection, revealed that IFN-γ secreting MTB specific CD4+T cells correlated 
poorly with protection and was more likely a reflection of MTB antigen load rather than 
protection (155).  The investigation of vaccine induced MTB specific T cells in human 
adults and infants have revealed T cells with complex phenotypic and polyfunctional 
cytokine secreting profiles (138)(139).  These polyfunctional MTB specific T cells have 
been detected in HIV infected people, and were inversely correlated with HIV viral load 
(156).   
 
Missed data, is a concern in longtitudinal studies.  It results in reduction of sample size 
and possibly loss of power.  In our setting, the most frequent cause of missed time points, 
was temporary relocation of the study participants.  We analysed the available data using 
statistical measures designed to handles missing data, however, future longtitudinal 
studies planned for this setting should carefully consider this factor (158). 
 
Despite the limitations, the results of this study provide insight into the reconstitution of 
the presumed protective immune responses, during cART, in MTB sensitised people.  
cART is associated with an absolute increase in effector function while the proportional 
measure declines.  The correlate most strongly associated with increased cART mediated, 
MTB specific immunity, was the central memory response.  This may contribute 
significant considerations to the design of new vaccines as well as the monitoring of 
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University of Cape Town. 
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Ronnett Seldon, Graeme Meintjes, Priscilla Mouton, Willem A. Hanekom, 
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Appendix 3.  Individual tables of flow cytometry and ELISpot results. 
Table 11.  CD4 Counts (cells/µl) (Figure 7). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 141 NA NA NA 183 234 209 
2 161 NA NA NA 302 362 413 
3 63 NA NA NA 353 NA 302 
4 23 NA NA NA 295 358 472 
5 147 NA NA NA 567 418 439 
6 22 NA NA NA 126 145 270 
7 309 NA NA NA 356 489 NA 
8 93 NA NA 165 179 NA 293 
10 108 NA 154 NA 104 239 232 
11 131 NA 360 341 535 NA 552 
13 86 212 230 261 295 261 357 
14 103 159 178 251 336 NA 323 
17 61 NA NA 160 117 206 162 
20 118 132 318 236 248 278 323 
21 99 NA NA 511 194 276 429 
22 90 188 148 158 140 121 89 
24 11 48 63 107 209 257 253 
25 40 NA 41 165 115 126 240 
28 3 NA NA 175 312 330 531 
NA= Not available 
 
Table 12.  CD4+ T cells (% of PBMC) (Figure 12). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA 51 49 NA 38 39 32 
2 51 44 60 NA 51 56 49 
3 28 34 38 NA 36 NA 43 
4 6 3 4 7 14 32 40 
5 33 33 41 41 41 39 39 
6 8 10 34 7 36 14 15 
7 24 20 17 17 17 27 33 
8 NA 36 NA 11 31 40 36 
10 11 9 14 14 18 14 14 
11 23 15 14 21 25 28 30 
13 20 17 19 28 28 33 44 
14 12 15 17 19 21 NA 15 
17 7 17 NA 1 3 3 3 
20 13 7 10 11 8 13 12 
21 13 21 14 24 27 35 39 
22 14 14 12 11 10 8 5 
24 1 3 1 3 NA 34 42 
25 1 NA 1 2 1 2 2 
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Table 13.  Naïve CD4+T cells (% of PBMC) (Figure 14). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 8 10 15 NA 22 28 25 
2 10 12 16 NA 14 15 15 
3 13 21 21 NA 25 NA 29 
4 2 6 10 16 15 22 24 
5 9 12 11 9 28 33 31 
6 2 3 4 5 8 14 15 
7 15 13 9 12 23 24 26 
8 NA 7 NA 15 10 9 14 
10 12 14 13 17 24 29 16 
11 9 16 18 15 19 19 20 
13 4 6 15 7 12 9 14 
14 13 15 15 18 21 NA 19 
17 2 21 NA 8 7 8 8 
20 14 19 19 14 15 13 11 
21 5 8 9 9 9 14 9 
22 9 9 9 9 8 7 7 
24 3 6 7 10 10 20 20 
25 2 NA 6 6 8 8 9 
28 0 2 4 8 11 14 18 
 
 
Table 14.  Central memory CD4+T cells, CD4+CD27+CD45RA- (% of PBMC) 
                  (Figure 15A). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA 38 38 NA 42 50 49 
2 16 38 29 NA 35 32 39 
3 47 48 32 NA 42 NA 45 
4 21 31 31 39 44 41 41 
5 41 45 37 40 41 53 51 
6 50 47 25 43 46 59 61 
7 53 32 65 68 75 67 63 
8 NA 46 NA 52 62 48 49 
10 49 51 47 49 57 48 41 
11 61 53 57 71 64 57 58 
13 NA 38 38 NA 42 50 49 
14 16 38 29 NA 35 32 39 
17 47 48 32 NA 42 NA 45 
20 21 31 31 39 44 41 41 
21 41 45 37 40 41 53 51 
22 50 47 25 43 46 59 61 
24 53 32 65 68 75 67 63 
25 NA 46 NA 52 62 48 49 













Table 15.  Central memory CD4+T cells, CD4+CD27+CCR5- (% of PBMC)(Figure 15B). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 81 87 85 NA 77 80 73 
2 84 84 88 NA 80 85 82 
3 83 82 64 NA 76 NA 80 
4 28 34 36 42 59 59 74 
5 86 82 76 75 81 85 77 
6 58 53 33 49 76 63 67 
7 81 NA 79 85 83 85 90 
8 NA NA NA 70 86 78 87 
10 62 58 56 61 74 37 54 
11 78 62 66 88 83 84 86 
13 63 49 69 85 71 75 76 
14 54 73 78 70 74 NA 69 
17 11 55 NA 30 29 35 38 
20 45 58 62 67 62 69 70 
21 73 79 62 70 75 81 77 
22 31 28 28 28 24 22 16 
24 16 19 32 58 47 65 71 
25 2 NA 13 27 77 19 28 
28 6 12 13 24 41 43 62 
 
 
Table 16.  Effector CD4+T cells, CD4+CCR5+ (% of PBMC) (Figure 16A). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 0 5 3 NA 1 5 5 
2 1 6 2 NA 1 1 2 
3 1 7 7 NA 1 NA 2 
4 2 16 24 14 5 8 2 
5 4 5 28 5 4 3 4 
6 18 10 29 5 5 7 5 
7 4 15 3 2 1 2 2 
8 NA NA NA 5 1 8 3 
10 5 4 3 4 1 1 8 
11 6 1 0 3 3 3 1 
13 12 23 1 1 6 4 3 
14 10 2 2 4 6 NA 5 
17 14 9 NA 14 4 6 6 
20 11 5 5 3 10 3 5 
21 5 5 7 6 5 3 3 
22 6 3 4 7 5 5 7 
24 13 20 10 30 5 3 1 
25 12 NA 22 13 20 18 4 












Table 17.  Effector CD4+T cells, CD4+CCR7-CD27- (% of PBMC) (Figure 16A). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA NA 15 NA 24 14 25 
2 NA 18 12 20 18 14 18 
3 NA 16 25 NA 23 NA 15 
4 71 44 62 49 39 30 23 
5 13 12 18 17 11 14 20 
6 22 32 46 39 23 37 27 
7 15 38 16 17 10 13 7 
8 NA 30 NA 32 14 21 11 
10 35 41 43 36 25 62 46 
11 16 32 36 15 15 18 19 
13 37 48 30 13 24 22 25 
14 43 27 22 25 23 NA 30 
17 89 44 NA 65 67 64 61 
20 53 37 39 34 37 27 27 
21 27 17 41 32 23 16 24 
22 68 71 71 70 74 76 82 
24 84 74 70 48 99 35 27 
25 92 NA 80 70 1 71 72 
28 84 73 83 71 63 52 41 
 
 
Table 18.  CD4+CD69+ T cells, (% of PBMC) (Figure 18A). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 2 NA NA 12 1 2 NA 
2 1 NA 1 10 1 0 2 
3 NA NA 2 NA 2 NA 1 
4 NA NA 1 1 1 3 1 
5 NA 1 1 2 1 1 1 
6 1 2 18 1 2 4 4 
7 2 1 1 1 1 2 1 
8 NA 1 NA 1 2 2 2 
10 47 3 2 2 1 2 2 
11 5 1 2 2 1 1 1 
13 4 2 2 2 1 1 2 
14 2 2 1 2 1 NA 1 
17 3 2 NA 2 2 2 1 
20 1 1 1 40 2 1 2 
21 2 1 1 1 2 1 4 
22 1 3 1 2 1 2 2 
24 1 6 1 1 1 1 1 
25 4 NA 2 5 NA 12 1 












Table 19.  CD4+CD45RO+CD69+ T cells (% of PBMC) (Figure 18B). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA NA NA NA 9 1 1 
2 NA NA NA NA 1 0 2 
3 NA NA NA NA 1 NA 1 
4 NA NA 1 1 1 3 1 
5 NA 3 2 NA 1 1 1 
6 6 4 NA 3 2 3 2 
7 2 0 3 3 2 1 1 
8 NA 1 NA 1 1 1 1 
10 NA 5 2 1 1 2 1 
11 4 1 2 2 1 1 1 
13 3 2 2 2 3 1 1 
14 2 2 1 2 1 NA 1 
17 2 2 NA 1 2 1 1 
20 1 1 1 34 1 2 2 
21 1 0 1 1 2 1 4 
22 1 2 1 2 1 4 2 
24 1 6 1 0 1 1 1 
25 3 NA 2 4 0 12 1 
28 NA 5 7 4 2 1 3 
 
 
Table 20.  CD4+CD25+ T cells, (% of PBMC) (Figure 19). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA NA NA NA 9 1 1 
2 NA NA NA NA 1 0 2 
3 NA NA NA NA 1 NA 1 
4 NA NA 1 1 1 3 1 
5 NA 3 2 NA 1 1 1 
6 6 4 NA 3 2 3 2 
7 2 0 3 3 2 1 1 
8 NA 1 NA 1 1 1 1 
10 NA 5 2 1 1 2 1 
11 4 1 2 2 1 1 1 
13 3 2 2 2 3 1 1 
14 2 2 1 2 1 NA 1 
17 2 2 NA 1 2 1 1 
20 1 1 1 34 1 2 2 
21 1 0 1 1 2 1 4 
22 1 2 1 2 1 4 2 
24 1 6 1 0 1 1 1 
25 3 NA 2 4 0 12 1 













Table 21.  CD4+IFN-γ+ T cells, (% of PBMC), (Figure 20A). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA 1.2 0.3 NA 0.2 0.1 0.1 
2 1.3 0.8 1.0 NA 0.1 0.1 0.2 
3 1.4 1.1 0.3 NA 0.2 NA 0.3 
4 3.4 0.5 1.8 0.4 1.4 0.7 0.5 
5 13.8 1.9 2.9 1.2 0.4 0.7 0.4 
6 0.9 1.3 1.7 0.9 2.2 0.5 0.5 
7 0.4 1.4 0.7 0.8 0.2 0.1 0.2 
8 NA 1.4 NA 0.5 1.6 1.1 1.2 
10 0.3 0.8 0.3 0.1 0.1 0.2 0.5 
11 0.2 0.2 0.1 0.1 0.2 0.3 0.2 
13 0.2 0.2 0.2 0.4 0.4 0.3 0.2 
14 0.3 0.3 0.3 0.3 0.6 NA 0.3 
17 0.3 1.3 NA 0.6 0.4 0.3 0.5 
20 1.4 1.3 2.3 2.7 1.1 0.4 0.3 
21 0.5 0.5 0.3 0.3 0.9 0.3 0.4 
22 1.3 0.9 0.6 0.8 0.6 0.5 0.4 
24 1.1 0.8 0.6 0.3 0.6 0.6 0.7 
25 0.9 NA 0.7 2.9 0.1 1.6 1.2 
28 1.7 0.7 0.8 0.3 0.3 0.2 0.1 
 
 
Table 22.  CD4+IL2+ T cells, (% of PBMC) (Figure 20B). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 0.8 1.0 0.3 NA 0.2 0.3 0.3 
2 1.2 0.1 0.1 NA 0.1 0.4 0.4 
3 0.4 0.4 0.2 NA 0.1 NA 0.2 
4 4.7 2.7 2.5 1.9 3.9 1.5 0.4 
5 0.6 0.3 0.2 0.5 0.1 NA 0.1 
6 1.4 0.4 1.0 1.0 0.7 1.2 0.4 
7 0.5 3.4 0.5 0.4 0.1 0.1 0.2 
8 NA 1.1 NA 0.4 0.6 0.2 0.1 
10 4.3 10.7 0.3 0.2 0.0 0.1 0.2 
11 NA 0.1 0.4 0.6 0.2 0.1 0.2 
13 0.4 0.3 0.2 0.3 0.2 0.5 0.1 
14 0.2 5.6 0.2 0.1 0.3 NA 0.2 
17 0.2 1.1 NA 0.1 0.3 0.1 0.2 
20 0.3 0.3 1.0 1.0 0.5 0.2 NA 
21 0.1 15.0 0.2 0.2 0.2 0.1 0.2 
22 NA NA 13.9 0.2 0.7 0.4 0.1 
24 0.4 3.5 0.0 0.2 0.0 0.1 0.3 
25 5.0 NA 0.2 1.1 1.1 1.2 0.6 













Table 23.  CD4+IL10+ T cells, (% of PBMC) (Figure 20C). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA 1.0 0.3 NA 0.1 0.1 0.5 
2 0.3 0.2 0.2 NA 0.2 0.1 0.4 
3 0.1 0.3 0.2 NA 0.1 NA 0.2 
4 2.2 4.8 2.8 1.4 1.1 0.6 0.5 
5 0.4 0.1 0.4 0.3 0.2 NA 0.1 
6 0.4 0.1 0.9 1.0 0.1 0.4 0.4 
7 0.8 1.6 0.4 0.8 0.1 0.3 0.2 
8 NA 1.9 NA 0.3 0.2 0.1 0.1 
10 1.9 3.0 0.1 0.1 0.4 0.1 0.4 
11 NA 0.6 0.6 0.8 0.1 0.1 0.4 
13 0.2 0.4 0.1 1.1 0.5 0.3 0.1 
14 0.2 4.7 0.4 0.3 0.4 NA 0.1 
17 0.3 0.2 NA 0.1 0.4 0.2 0.2 
20 0.2 0.3 0.6 0.1 0.4 0.1 NA 
21 0.2 0.2 0.8 0.3 0.2 0.3 0.8 
22 NA NA 0.4 0.5 0.5 0.5 0.9 
24 0.4 3.6 0.4 0.3 0.1 0.2 0.3 
25 5.7 NA 0.8 0.4 0.6 1.4 0.1 
28 0.8 3.2 3.5 3.7 0.6 1.1 0.8 
 
 
Table 24.  CD4+TNF+ T cells, (% of PBMC) (Figure 20D). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA 1.2 0.1 NA 0.1 0.1 0.1 
2 0.0 0.0 0.3 NA 0.1 0.3 0.2 
3 0.2 0.1 0.1 NA 0.6 NA 0.1 
4 0.0 0.0 0.8 0.5 2.0 1.0 0.6 
5 0.6 0.2 0.4 0.3 0.4 NA 0.4 
6 0.8 0.8 1.2 1.0 1.5 0.8 0.6 
7 0.2 4.5 1.4 1.2 0.1 0.1 0.2 
8 NA 1.4 NA 0.5 0.0 0.7 0.7 
10 1.8 0.0 0.7 0.0 0.1 0.1 0.1 
11 NA 0.1 0.2 0.0 0.1 0.1 0.7 
13 0.4 0.3 0.0 1.6 0.2 0.4 0.1 
14 0.3 0.7 0.4 0.2 0.1 NA 0.3 
17 0.2 2.0 NA 0.3 0.2 0.2 0.2 
20 1.1 1.3 2.7 3.5 1.1 0.4 NA 
21 0.1 0.2 0.4 0.6 1.0 0.2 0.3 
22 NA NA 0.6 0.2 0.3 0.1 0.3 
24 0.2 0.6 0.1 0.4 0.5 0.3 0.7 
25 2.0 NA 0.3 3.0 1.7 1.8 1.2 












Table 25.  CD8+ T cells (% of PBMC), (Figure 24). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA NA NA NA 42 26 32 
2 NA NA NA NA 63 63 63 
3 NA NA NA NA 46 NA 29 
4 NA 69 62 50 57 52 45 
5 NA NA 48 41 47 50 56 
6 23 14 NA 35 70 45 35 
7 43 40 47 49 49 48 45 
8 NA 64 NA 40 72 63 65 
10 70 68 73 67 56 68 64 
11 55 57 51 52 52 56 56 
13 49 66 45 66 62 73 53 
14 46 61 44 39 64 NA 43 
17 16 42 NA 45 42 44 43 
20 59 54 57 58 NA 68 64 
21 95 71 72 72 NA 61 68 
22 56 54 58 61 61 50 48 
24 64 55 70 70 64 56 53 
25 35 NA 39 39 48 51 66 
28 55 43 NA 55 55 51 57 
 
 
Table 26.  B cells CD3-CD19+ (% of Lymphocytes), (Figure 26). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA NA NA NA 9.7 11.4 8.8 
2 NA NA NA NA 3.9 3.3 1.5 
3 NA NA NA NA 0.7 NA 0.6 
4 NA NA 2.8 0.8 0.5 0.3 0.5 
5 NA 6.0 3.9 6.0 5.3 5.4 3.5 
6 10.4 15.9 NA 5.3 1.4 2.9 2.7 
7 6.6 1.1 1.2 1.5 2.9 2.2 1.9 
8 NA 1.2 NA 5.1 3.0 1.6 1.4 
10 1.3 0.7 0.6 0.6 1.9 1.1 0.6 
11 0.9 1.0 0.5 0.6 0.7 0.7 0.6 
13 6.1 6.5 4.7 0.6 1.3 1.3 1.0 
14 2.1 3.5 4.5 1.9 1.9 NA 0.7 
17 NA 5.5 NA 1.8 0.7 1.4 1.3 
20 3.0 2.6 2.6 5.2 NA 5.7 4.6 
21 4.6 3.7 2.2 3.0 2.8 3.3 2.3 
22 2.4 1.6 2.4 2.4 2.5 3.0 1.9 
24 1.5 0.9 0.4 1.2 1.5 1.4 0.8 
25 1.6 NA 0.4 0.3 0.5 NA 0.3 












Table 27.  NK cells CD3-CD56+ (% of Lymphocytes), (Figure 27A). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA NA NA NA 17 10 17 
2 NA NA NA NA 3 2 4 
3 NA NA NA NA 9 NA 9 
4 NA NA 11 13 8 5 8 
5 NA 9 4 5 4 6 4 
6 42 30 NA 18 5 9 3 
7 3 2 3 2 3 2 2 
8 NA 4 NA 13 6 2 8 
10 5 7 7 6 7 8 7 
11 9 8 3 17 4 11 12 
13 2 2 5 2 1 4 3 
14 6 4 6 6 6 NA 9 
17 NA 16 NA 21 28 25 18 
20 4 3 2 4 NA 3 8 
21 3 5 2 2 2 3 1 
22 3 2 4 10 11 1 12 
24 17 8 3 6 9 11 13 
25 2 NA 1 11 12 NA 10 
28 27 22 9 6 10 8 4 
 
 
Table 28.  NKT cells CD3+CD56+ (% of Lymphocytes), (Figure 27A). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA NA NA NA 17 10 17 
2 NA NA NA NA 3 2 4 
3 NA NA NA NA 9 NA 9 
4 NA NA 11 13 8 5 8 
5 NA 9 4 5 4 6 4 
6 42 30 NA 18 5 9 3 
7 3 2 3 2 3 2 2 
8 NA 4 NA 13 6 2 8 
10 5 7 7 6 7 8 7 
11 9 8 3 17 4 11 12 
13 2 2 5 2 1 4 3 
14 6 4 6 6 6 NA 9 
17 NA 16 NA 21 28 25 18 
20 4 3 2 4 NA 3 8 
21 3 5 2 2 2 3 1 
22 3 2 4 10 11 1 12 
24 17 8 3 6 9 11 13 
25 2 NA 1 11 12 NA 10 












Table 29.  IFN-γ SFC/106 PBMC in response to PPD restimulation (Figure 30). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA NA 637 NA 477 NA 13 
2 1 NA 7 NA 1 57 68 
3 NA 13 22 NA 17 NA 1 
4 1 1 277 77 653 447 40 
5 73 NA 43 37 90 300 NA 
6 7 7 NA 173 237 220 NA 
7 1 3 300 227 30 100 60 
8 7 NA NA 210 942 NA 644 
10 1 1 3 3 NA 1 69 
11 1 17 7 17 NA 10 20 
13 97 23 1 139 56 43 NA 
14 7 47 33 NA NA NA NA 
17 26 335 NA 848 713 NA NA 
20 NA 1 53 828 NA NA 60 
21 7 1096 1122 1508 NA NA 90 
22 1059 1297 624 109 NA NA NA 
24 NA NA 620 851 17 571 245 
25 NA NA 50 657 NA 648 7 
28 NA 203 83 43 100 NA 250 
 
 
Table 30.  Summed IFN-γ SFC/106 PBMC in response to ESAT-6 and CFP-10          
        restimulation (Figure 31). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
1 NA NA 40 NA 157 NA 653 
2 127 NA 1427 NA 3 1010 2204 
3 NA 1580 607 NA 60 NA 27 
4 223 507 1197 493 1273 830 343 
5 103 NA 160 70 483 1180 NA 
6 20 113 NA 30 680 187 NA 
7 1 23 3 13 200 707 573 
8 1223 NA NA 927 847 NA 548 
10 147 333 443 470 NA 181 1274 
11 1133 1147 960 1120 NA 439 1531 
13 553 570 477 950 927 1126 NA 
14 147 1087 517 NA NA NA NA 
17 20 120 NA 634 488 NA NA 
20 NA 79 406 1095 NA NA 1519 
21 1 422 1069 1360 NA NA 2054 
22 1195 1670 709 852 NA NA NA 
24 NA 480 208 1029 1426 2237 1793 
25 NA NA 1485 1627 NA 1976 NA 












Table 31.  IFN-γ SFC/106 PBMC in response to ACR1 restimulation (Figure 33A). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
2 70 0 830 NA 7 173 864 
4 170 287 450 210 103 880 83 
5 67 NA 113 60 30 93 NA 
6 27 20 NA 33 37 20 NA 
7 0 10 0 7 25 23 60 
10 53 147 40 33 NA 162 1313 
11 137 190 60 293 NA 244 1247 
13 17 67 33 1000 1261 1023 NA 
21 861 1799 551 858 NA NA 1329 
24 NA NA 934 1238 623 581 497 
 
 
Table 32.  IFN-γ SFC/106 PBMC in response to ACR2 restimulation (Figure 33B). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
2 0 0 797 NA 17 127 1384 
4 43 233 953 303 943 1200 57 
5 77 NA 73 23 20 283 NA 
6 23 63 NA 7 70 157 NA 
7 0 0 0 0 5 10 87 
10 43 143 27 87 NA 320 2313 
11 150 187 110 417 NA 1132 1436 
13 3 23 0 1152 1716 941 NA 
21 13 323 515 198 NA NA 443 
24 NA NA 746 865 799 838 577 
 
 
Table 33.  IFN-γ SFC/106 PBMC in response to TB10.3 restimulation (Figure 34). 
Study number Week 0 Week 2 Week 4 Week 12 Week 24 Week 36 Week 48 
2 27 0 673 NA 10 210 1296 
4 103 277 1023 297 707 987 33 
5 40 NA 380 33 30 223 NA 
6 37 10 NA 13 53 43 NA 
7 0 13 3 13 320 17 73 
10 33 150 217 67 NA 297 2030 
11 233 320 147 323 NA 812 1343 
13 60 97 0 1211 201 1363 NA 
21 92 125 363 406 NA NA 716 
24 NA NA 1660 508 813 1498 1387 
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